thalidomide has been researched along with Angiogenesis, Pathologic in 235 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. ( Cheng, AL; Hsiao, CH; Hsu, C; Hsu, CH; Huang, CC; Lee, KD; Lin, ZZ; Lu, YS; Shao, YY; Shen, YC, 2012) |
| "To evaluate the efficacy and adverse events (AEs) of thalidomide in previously treated, measurable, persistent or recurrent leiomyosarcoma (LMS) of the uterus, and to explore associations between angiogenic markers and treatment or clinical outcome." | 9.12 | A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. ( Benbrook, D; Darcy, KM; McMeekin, DS; Sill, MW; Stearns-Kurosawa, DJ; Waggoner, S; Webster, K, 2007) |
| "Thalidomide (THAL) is currently used as a novel drug in patients with chemotherapy resistant or relapsed multiple myeloma." | 9.11 | The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. ( Bojarska-Junak, A; Dmoszynska, A; Manko, J; Podhorecka, M; Rolinski, J; Skomra, D, 2005) |
| "Thalidomide is the first drug in over 20 years to demonstrate clinically significant activity in patients with multiple myeloma." | 8.81 | Thalidomide for the treatment of relapsed and refractory multiple myeloma. ( Cool, RM; Herrington, JD, 2002) |
| "This study aimed to evaluate the effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in BALB/c female mice." | 8.12 | The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo. ( Goleh, Z; Mokhtari-Dizaji, M; Toliyat, T, 2022) |
| "we aimed to explore the role of thalidomide in breast cancer by using a mouse 4T1 breast tumor model." | 7.96 | Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice. ( MengLv, L; Shen, Y; Wang, F; Wang, X; Yang, J; Zhang, X, 2020) |
| "The total psoriasis area and severity index scores in the moderate- and high-dose thalidomide and acitretin groups decreased significantly (p<0." | 7.88 | Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model. ( Gao, Q; Liu, JH; Luo, DQ; Wang, F; Wu, HH; Zhao, YK, 2018) |
| "To develop thalidomide-loaded poly-lactide-co-glycolide implants and evaluate its in vivo release and biological activity against inflammation and angiogenesis after subcutaneous administration." | 7.81 | Development of thalidomide-loaded biodegradable devices and evaluation of the effect on inhibition of inflammation and angiogenesis after subcutaneous application. ( Andrade, SP; Batista, LF; da Nova Mussel, W; da Silva, GR; de Souza, PA; Fialho, SL; Pereira, BG; Serakides, R; Silva-Cunha, A, 2015) |
| "Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility." | 7.78 | A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. ( Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B, 2012) |
| "To determine the in vivo and in vitro antiangiogenic power of lenalidomide, a "lead compound" of IMiD immunomodulatory drugs in bone marrow (BM) endothelial cells (EC) of patients with multiple myeloma (MM) in active phase (MMEC)." | 7.77 | Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. ( Basile, A; Berardi, S; Caivano, A; Capalbo, S; Cascavilla, N; Coluccia, AM; Dammacco, F; de Luca, E; De Luisi, A; Di Pietro, G; Ditonno, P; Ferrucci, A; Guarini, A; Maffia, M; Moschetta, M; Pieroni, L; Quarta, G; Ranieri, G; Ria, R; Ribatti, D; Urbani, A; Vacca, A, 2011) |
| "To investigate the effects of thalidomide on angiogenesis, tumor growth and metastasis of hepatocellular carcinoma in nude mice." | 7.73 | Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. ( Liu, ZS; Sun, Q; Zhang, ZL, 2005) |
| "To prospectively evaluate the feasibility of using power Doppler ultrasonography (US) and measurement of circulating angiogenic factors to assess the antiangiogenic effect of thalidomide in hepatocellular carcinoma." | 7.73 | Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. ( Chen, CN; Chen, LT; Cheng, AL; Hsieh, FJ; Hsu, C; Wu, CY, 2005) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 7.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "We sought to investigate whether thalidomide is able to produce tumor vascular changes in patients with untreatable hepatocellular carcinoma (HCC) that can be detected using microbubble contrast agents." | 7.73 | Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results. ( Bertolotto, M; Cova, MA; Crocè, LS; Gasparini, C; Nascimben, F; Pozzato, G; Tiribelli, C, 2006) |
| "s-Thalidomide has proven efficacy in multiple myeloma." | 7.72 | s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. ( Chaplin, T; Joel, SP; Liu, WM; Malpas, JS; Propper, DJ; Shahin, S; Strauss, SJ; Young, BD, 2004) |
| "Recently a growing number of studies have suggested the efficacy of thalidomide (THAL) in the treatment of relapsed or resistant multiple myeloma." | 7.71 | Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. ( Bojarska-Junak, A; Dmoszyńska, A; Domański, D; Hus, M; Roliński, J; Soroka-Wojtaszko, M, 2002) |
| "Thalidomide was given orally at a daily dose of 200 mg/day, which was then escalated every 2 weeks by 200 mg/day as tolerated to a maximum of 800 mg/day." | 6.71 | Phase II study of thalidomide in patients with metastatic malignant melanoma. ( Cancela, AI; Costa, TD; Di Leone, LP; Fernandes, S; Reiriz, AB; Richter, MF; Schwartsmann, G, 2004) |
| "Thalidomide is a drug with interesting therapeutic properties but also with severe side effects which require a careful and monitored use." | 6.55 | A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma. ( Adriani, G; Carocci, A; Catalano, A; Cavalluzzi, MM; Corbo, F; Franchini, C; Lentini, G; Mercurio, A; Rao, L; Vacca, A, 2017) |
| "Diabetic retinopathy is an ocular complication associated with the chronic endocrine disorder of diabetes mellitus." | 6.55 | Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. ( Behl, T; Goel, H; Kaur, I; Kotwani, A, 2017) |
| " These studies provide further support for clinical trials evaluating OPZ in combination with Pom and Dex." | 6.55 | Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). ( Berenson, JR; Chen, H; Gillespie, A; Li, M; Sanchez, E; Tang, G; Wang, CS, 2017) |
| "Thalidomide (Thal) has antiangiogenic and immunomodulatory activity." | 6.43 | Thalidomide in multiple myeloma. ( Glasmacher, A; Goldschmidt, H; Hillengass, J; Moehler, TM, 2006) |
| "Thalidomide is an infamous molecule for its teratogenicity, yet it possesses potent immunomodulatory, anti-angiogeneic and, in higher concentrations, direct anti-myeloma-cell properties." | 6.41 | [Role of thalidomide in the treatment of multiple myeloma]. ( Jákó, J; Mikala, G; Vályi-Nagy, I, 2001) |
| "Treatment with lenalidomide reduced tumor vessel density (p = 0." | 5.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "Lenalidomide is a novel analogue of thalidomide and has anti‑inflammatory, immunomodulatory and anti‑angiogenic effects." | 5.43 | Lenalidomide induces apoptosis and inhibits angiogenesis via caspase‑3 and VEGF in hepatocellular carcinoma cells. ( Ding, Y; Jiang, C; Qu, Z; Wu, J, 2016) |
| "Thalidomide precipitates were observed when its DMSO solution was added to the culture medium." | 5.42 | Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. ( Cheng, CC; Chiu, TH; Huang, YT; Lai, PC, 2015) |
| "Thalidomide has proven to exert anti-inflammatory, anti-proliferative and anti-angiogenic activities in both neoplastic and non-neoplastic conditions." | 5.38 | Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. ( Alves Neves Diniz Ferreira, M; Cândida Araújo E Silva, A; da Silva Vieira, T; Dantas Cassali, G; Fonseca de Carvalho, L; Maria de Souza, C; Passos Andrade, S; Teresa Paz Lopes, M, 2012) |
| "Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by progressive anemia, massive splenomegaly, leukoerythroblastosis, extramedullary hematopoiesis and in about 50% of cases the presence of JAK2V617F mutation." | 5.35 | Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. ( Colagrande, M; Coletti, G; Di Ianni, M; Fargnoli, MC; Lapecorella, M; Moretti, L; Peris, K; Tabilio, A, 2009) |
| "Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis." | 5.34 | Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. ( Hisamori, S; Kadokawa, Y; Kubo, H; Mishima, M; Nakano, T; Tabata, C; Tabata, R; Takahashi, M, 2007) |
| "Thalidomide was administered daily at doses ranging from 50 to 300 mg/kg by intraperitoneal injection." | 5.33 | Effect of thalidomide on colorectal cancer liver metastases in CBA mice. ( Christophi, C; Daruwalla, J; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2005) |
| "Thalidomide is reported to be an anti-angiogenic agent, which is currently in phase II clinical trials for the treatment of advanced malignancies." | 5.32 | Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. ( Jiang, W; Li, QQ; Li, X; Liu, X; Liu, Y; Reed, E; Wang, J; Wang, Z; Zhang, Y, 2003) |
| "Thalidomide treatment did not significantly alter tumor growth as compared with controls." | 5.32 | Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. ( Beck, L; Frischer, JS; Huang, J; Kadenhe-Chiweshe, A; Kaicker, S; Kandel, JJ; McCrudden, KW; New, T; Serur, A; Yamashiro, DJ; Yokoi, A, 2003) |
| "Thalidomide has recently been shown to antagonize basic fibroblast growth factor-induced angiogenesis in the rat corneal micropocket assay." | 5.29 | The effect of thalidomide on experimental tumors and metastases. ( Clow, KA; Fryer, KH; Hayes, MM; Minchinton, AI; Wendt, KR, 1996) |
| "Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. ( Cheng, AL; Hsiao, CH; Hsu, C; Hsu, CH; Huang, CC; Lee, KD; Lin, ZZ; Lu, YS; Shao, YY; Shen, YC, 2012) |
| "To evaluate the efficacy and adverse events (AEs) of thalidomide in previously treated, measurable, persistent or recurrent leiomyosarcoma (LMS) of the uterus, and to explore associations between angiogenic markers and treatment or clinical outcome." | 5.12 | A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. ( Benbrook, D; Darcy, KM; McMeekin, DS; Sill, MW; Stearns-Kurosawa, DJ; Waggoner, S; Webster, K, 2007) |
| "Thalidomide (THAL) is currently used as a novel drug in patients with chemotherapy resistant or relapsed multiple myeloma." | 5.11 | The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. ( Bojarska-Junak, A; Dmoszynska, A; Manko, J; Podhorecka, M; Rolinski, J; Skomra, D, 2005) |
| " Among the putative inhibitors of angiogenesis, thalidomide has demonstrated a considerable efficacy in myelodysplastic syndromes (MDS) and AML with overall response rates up to 56% and 25%, respectively." | 4.82 | Thalidomide for the treatment of acute myeloid leukemia. ( Berdel, WE; Bieker, R; Kessler, T; Kienast, J; Mesters, RM; Padró, T; Steins, MB, 2003) |
| " Thalidomide which has antiangiogenic effects and direct cytotoxic effects was found to be effective in multiple myeloma and is considered as an established treatment modality for patients with refractory or relapsed multiple myeloma." | 4.82 | Antiangiogenic therapy in hematologic malignancies. ( Goldschmidt, H; Hillengass, J; Ho, AD; Moehler, TM, 2004) |
| "Thalidomide is the first drug in over 20 years to demonstrate clinically significant activity in patients with multiple myeloma." | 4.81 | Thalidomide for the treatment of relapsed and refractory multiple myeloma. ( Cool, RM; Herrington, JD, 2002) |
| " When all conventional therapy has failed, an angiogenesis inhibitor may be successfully used alone, as has been demonstrated in the treatment of multiple myeloma by thalidomide." | 4.81 | Angiogenesis-dependent diseases. ( Folkman, J, 2001) |
| "This study aimed to evaluate the effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in BALB/c female mice." | 4.12 | The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo. ( Goleh, Z; Mokhtari-Dizaji, M; Toliyat, T, 2022) |
| "Our findings revealed a key role for EGFL6 in SBVM pathogenesis and provided a mechanism explaining why thalidomide can cure small bowel bleeding resulting from SBVM." | 3.96 | Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation. ( Gao, YJ; Ge, ZZ; Liang, Q; Lin, XL; Tang, CT; Tang, MY; Wu, S; Zhang, QW, 2020) |
| "we aimed to explore the role of thalidomide in breast cancer by using a mouse 4T1 breast tumor model." | 3.96 | Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice. ( MengLv, L; Shen, Y; Wang, F; Wang, X; Yang, J; Zhang, X, 2020) |
| "The total psoriasis area and severity index scores in the moderate- and high-dose thalidomide and acitretin groups decreased significantly (p<0." | 3.88 | Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model. ( Gao, Q; Liu, JH; Luo, DQ; Wang, F; Wu, HH; Zhao, YK, 2018) |
| "Over the last few years, thalidomide has become one of the most important anti-tumour drugs for the treatment of relapsed-refractory multiple myeloma." | 3.85 | Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others. ( Akiyama, H; Hara, H; Inoue, Y; Shibata, N; Soloshonok, VA; Tokunaga, E, 2017) |
| "To develop thalidomide-loaded poly-lactide-co-glycolide implants and evaluate its in vivo release and biological activity against inflammation and angiogenesis after subcutaneous administration." | 3.81 | Development of thalidomide-loaded biodegradable devices and evaluation of the effect on inhibition of inflammation and angiogenesis after subcutaneous application. ( Andrade, SP; Batista, LF; da Nova Mussel, W; da Silva, GR; de Souza, PA; Fialho, SL; Pereira, BG; Serakides, R; Silva-Cunha, A, 2015) |
| "HIF-1α mRNA and protein were evaluated in patients with multiple myeloma endothelial cells (MMEC) at diagnosis, at relapse after bortezomib- or lenalidomide-based therapies or on refractory phase to these drugs, at remission; in endothelial cells of patients with monoclonal gammapathies of undetermined significance (MGUS; MGECs), and of those with benign anemia (controls)." | 3.80 | HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. ( Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A, 2014) |
| "Thalidomide has shown its efficacy in the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT) patients." | 3.79 | Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide. ( El Hajjam, M; Lacombe, P; Lacout, A; Marcy, PY, 2013) |
| "Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility." | 3.78 | A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. ( Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B, 2012) |
| "To determine the in vivo and in vitro antiangiogenic power of lenalidomide, a "lead compound" of IMiD immunomodulatory drugs in bone marrow (BM) endothelial cells (EC) of patients with multiple myeloma (MM) in active phase (MMEC)." | 3.77 | Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. ( Basile, A; Berardi, S; Caivano, A; Capalbo, S; Cascavilla, N; Coluccia, AM; Dammacco, F; de Luca, E; De Luisi, A; Di Pietro, G; Ditonno, P; Ferrucci, A; Guarini, A; Maffia, M; Moschetta, M; Pieroni, L; Quarta, G; Ranieri, G; Ria, R; Ribatti, D; Urbani, A; Vacca, A, 2011) |
| "Migration of HUVEC cells, the ability of HUVEC cells to form tubes, and proliferative capacity of a human ocular melanoma cell line were tested in the presence of lenalidomide and sorafenib alone and in combination." | 3.74 | Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. ( Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI, 2007) |
| "To investigate the effects of thalidomide on angiogenesis, tumor growth and metastasis of hepatocellular carcinoma in nude mice." | 3.73 | Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. ( Liu, ZS; Sun, Q; Zhang, ZL, 2005) |
| "To prospectively evaluate the feasibility of using power Doppler ultrasonography (US) and measurement of circulating angiogenic factors to assess the antiangiogenic effect of thalidomide in hepatocellular carcinoma." | 3.73 | Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. ( Chen, CN; Chen, LT; Cheng, AL; Hsieh, FJ; Hsu, C; Wu, CY, 2005) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 3.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "We sought to investigate whether thalidomide is able to produce tumor vascular changes in patients with untreatable hepatocellular carcinoma (HCC) that can be detected using microbubble contrast agents." | 3.73 | Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results. ( Bertolotto, M; Cova, MA; Crocè, LS; Gasparini, C; Nascimben, F; Pozzato, G; Tiribelli, C, 2006) |
| "We have previously shown that thalidomide and its potent immunomodulatory derivatives (IMiDs) inhibit the in vitro growth of multiple myeloma (MM) cell lines and patient MM cells that are resistant to conventional therapy." | 3.72 | Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. ( Anderson, KC; Catley, L; Davies, F; Hideshima, T; LeBlanc, R; Lentzsch, S; Lin, B; Podar, K; Stirling, DI, 2003) |
| "s-Thalidomide has proven efficacy in multiple myeloma." | 3.72 | s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. ( Chaplin, T; Joel, SP; Liu, WM; Malpas, JS; Propper, DJ; Shahin, S; Strauss, SJ; Young, BD, 2004) |
| "Recently a growing number of studies have suggested the efficacy of thalidomide (THAL) in the treatment of relapsed or resistant multiple myeloma." | 3.71 | Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. ( Bojarska-Junak, A; Dmoszyńska, A; Domański, D; Hus, M; Roliński, J; Soroka-Wojtaszko, M, 2002) |
| "Anti-angiogenesis therapy with thalidomide has been reported to have marked activity in multiple myeloma (MM)." | 3.70 | Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. ( Ackermann, J; Aletaha, K; Chott, A; Drach, J; Gisslinger, H; Huber, H; Kaufmann, H; Obermair, A; Schreiber, S; Urbauer, E, 2000) |
| "In the past three decades of cancer research, angiogenesis has been at its peak, where an anti-angiogenic agent inhibiting vascular endothelial growth factor acts as a promising substance to treat cancer." | 2.82 | Studying molecular signaling in major angiogenic diseases. ( Nathan, J; Palanivel, G; Shameera, R, 2022) |
| "Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors." | 2.79 | A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. ( Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA, 2014) |
| "Forty patients with Stage IC-IV ovarian cancer were randomly assigned to receive either carboplatin (AUC 7) intravenously every four weeks for up to six doses (n = 20) or carboplatin at the same dose and schedule, plus thalidomide 100 mg orally daily for six months (n = 20)." | 2.76 | A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. ( Blann, AD; Braybrooke, JP; Ganesan, TS; Han, C; Jenkins, A; Kaur, K; Madhusudan, S; Muthuramalingam, SR; Perren, T; Wilner, S, 2011) |
| " The recommended phase II dosing schedule is thalidomide 100 mg twice daily with docetaxel 25 mg/m(2)/week." | 2.73 | Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. ( Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Krishnamurthi, S; Ness, A; Nock, C; Remick, SC; Sanborn, SL, 2008) |
| "Thalidomide is a putative antiangiogenesis agent with activity in several hematologic malignancies." | 2.72 | Thalidomide therapy for myelofibrosis with myeloid metaplasia. ( Albitar, M; Cortes, JE; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Pierce, S; Thomas, DA; Verstovsek, S; Zeldis, J, 2006) |
| "Thalidomide was given orally at a daily dose of 200 mg/day, which was then escalated every 2 weeks by 200 mg/day as tolerated to a maximum of 800 mg/day." | 2.71 | Phase II study of thalidomide in patients with metastatic malignant melanoma. ( Cancela, AI; Costa, TD; Di Leone, LP; Fernandes, S; Reiriz, AB; Richter, MF; Schwartsmann, G, 2004) |
| "Thalidomide is a potent teratogen that causes dysmelia in humans." | 2.70 | A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. ( Chen, CC; Dahut, W; Dixon, S; Duray, P; Figg, WD; Floeter, MK; Gubish, E; Hamilton, M; Jones, E; Kohler, DR; Krüger, EA; Linehan, WM; Pluda, JM; Premkumar, A; Reed, E; Steinberg, SM; Tompkins, A, 2001) |
| " Overall, adverse events were fatigue, constipation, rash, and neuropathy (grade 1 to 2 in most patients)." | 2.70 | Efficacy and safety of thalidomide in patients with acute myeloid leukemia. ( Berdel, WE; Bieker, R; Buechner, T; Kessler, T; Kienast, J; Kropff, M; Mesters, RM; Padró, T; Ruiz, S; Steins, MB, 2002) |
| "Thalidomide is a teratogen that affects many organs but primarily induces limb truncations like phocomelia." | 2.55 | The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine. ( Jungck, D; Knobloch, J; Koch, A, 2017) |
| "Thalidomide is a drug with interesting therapeutic properties but also with severe side effects which require a careful and monitored use." | 2.55 | A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma. ( Adriani, G; Carocci, A; Catalano, A; Cavalluzzi, MM; Corbo, F; Franchini, C; Lentini, G; Mercurio, A; Rao, L; Vacca, A, 2017) |
| "Diabetic retinopathy is an ocular complication associated with the chronic endocrine disorder of diabetes mellitus." | 2.55 | Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. ( Behl, T; Goel, H; Kaur, I; Kotwani, A, 2017) |
| " These studies provide further support for clinical trials evaluating OPZ in combination with Pom and Dex." | 2.55 | Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). ( Berenson, JR; Chen, H; Gillespie, A; Li, M; Sanchez, E; Tang, G; Wang, CS, 2017) |
| "Hence, thalidomide is effective in cancer treatment due to the interaction between immune cells and tumor vasculature." | 2.53 | Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review). ( Li, S; Lv, M; Shen, Y; Wang, F; Wang, X; Yang, J; Zhang, X, 2016) |
| "Thalidomide was originally developed in 1954 as a sedative that was commonly used to ameliorate morning sickness." | 2.48 | Deciphering the mystery of thalidomide teratogenicity. ( Handa, H; Ito, T, 2012) |
| "Hemangiomas are benign neoplasms of the vasculature frequently encountered in children." | 2.47 | Hemangiomas - current therapeutic strategies. ( Mabeta, P; Pepper, MS, 2011) |
| "Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies." | 2.45 | Mechanism of action of lenalidomide in hematological malignancies. ( Das, B; Goel, S; Heuck, C; Kotla, V; Nischal, S; Verma, A; Vivek, K, 2009) |
| "The pathogenesis of POEMS syndrome is not well understood; however overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of the characteristic symptoms, including neuropathy." | 2.44 | [Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology]. ( Misawa, S, 2008) |
| "The growth of breast cancers, as is the case in other solid tumors, is dependent on the development of neo-vessels." | 2.44 | [Angiogenesis and breast cancer]. ( Bachelot, T; Blay, JY; Cassier, P; Ray-Coquard, I, 2007) |
| "Thalidomide was first used because of its anti-angiogenic properties, however it is the immunomodulatory actions that involve increasing host tumour-specific immunosurveillance by both T cell and natural killer cells which may be the most important mode of action." | 2.43 | The use of thalidomide in myeloma therapy as an effective anticancer drug. ( Brown, R; Gibson, J; Ho, PJ; Joshua, D; Sze, DM; Yang, S, 2006) |
| "Thalidomide (Thal) has antiangiogenic and immunomodulatory activity." | 2.43 | Thalidomide in multiple myeloma. ( Glasmacher, A; Goldschmidt, H; Hillengass, J; Moehler, TM, 2006) |
| "Thalidomide was first used during the 50's-60's, especially for morning sickness in pregnant women." | 2.42 | [Using thalidomide against pathological neovascularization]. ( Eisenkraft, A; Hourvitz, A; Luria, S; Robenshtok, E, 2003) |
| "It is now well established that cancer growth is increased by angiogenic factors and that inhibition of angiogenesis decreases growth and metastatic potential." | 2.42 | [Anti angiogenesis]. ( Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N, 2004) |
| "Thalidomide has long been recognized as an antiangiogenic molecule." | 2.42 | Thalidomide and analogues: current proposed mechanisms and therapeutic usage. ( Brennen, WN; Brown, ML; Capitosti, S; Cooper, CR; Sikes, RA, 2004) |
| "Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis." | 2.42 | Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. ( Arora, B; Mesa, R; Tefferi, A, 2004) |
| "Although multiple myeloma (MM) is sensitive to chemotherapy and radiation therapy, long-term disease-free survival is rare, and MM remains incurable despite conventional and high-dose therapies." | 2.42 | Targeting multiple myeloma cells and their bone marrow microenvironment. ( Cardinale, G; Gervasi, F; Pagnucco, G, 2004) |
| "Multiple myeloma is the second most common hematologic malignancy, with approximately 15,000 new cases each year in the United States." | 2.41 | Recent advances in multiple myeloma. ( Berenson, JR; Sjak-Shie, NN; Vescio, RA, 2000) |
| "Thalidomide is an infamous molecule for its teratogenicity, yet it possesses potent immunomodulatory, anti-angiogeneic and, in higher concentrations, direct anti-myeloma-cell properties." | 2.41 | [Role of thalidomide in the treatment of multiple myeloma]. ( Jákó, J; Mikala, G; Vályi-Nagy, I, 2001) |
| "Angiogenesis in Patients with Hematologic Malignancies The importance of angiogenesis for the progressive growth and viability of solid tumors is well established." | 2.41 | [Angiogenesis in patients with hematologic malignancies]. ( Berdel, WE; Bieker, R; Kessler, T; Kienast, J; Mesters, RM; Padró, T; Retzlaff, S; Steins, M, 2001) |
| "Thalidomide also has steroid-sparing properties, and it is particularly useful in treating oral and fistulous complications of Crohn's disease." | 2.41 | Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. ( Dassopoulos, T; Ehrenpreis, ED; Ginsburg, PM, 2001) |
| "Novel therapies in multiple myeloma (MM) target not only the tumor cell but also the bone marrow (BM) microenvironment." | 2.41 | Novel therapies targeting the myeloma cell and its bone marrow microenvironment. ( Anderson, KC; Chauhan, D; Hideshima, T; Podar, K; Richardson, P; Schlossman, RL, 2001) |
| "Thalidomide, which was developed as a nonbarbiturate sedative agent, was taken off the market in 1961 after it was linked to a spate of major birth defects." | 2.41 | Thalidomide: new indications? ( Combe, B, 2001) |
| "Additionally, multiple myeloma is primarily a disease of the elderly, many of whom cannot tolerate aggressive chemotherapy." | 2.41 | Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. ( Hussein, MA, 2002) |
| " In addition, antiangiogenic agents may be valuable for long-term administration to maintain tumor dormancy, because drug resistance does not develop and these agents have a sustained effect." | 2.40 | Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies. ( Baba, M; Kanai, T; Konno, H; Nakamura, S; Tanaka, T, 1999) |
| "Thalidomide is an effective drug in inflammatory bowel disease, which might be related to its multiple role in anti-inflammatory, immunoregulatory, and anti-angiogenesis." | 1.62 | Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2 in Crohn's Disease. ( Huang, Y; Shi, J; Wang, L; Wang, S; Xue, A; Zheng, C, 2021) |
| "In this study we subjected the gastric cancer cell line AGS to chronic exposure of 5-fluorouracil, cisplatin or paclitaxel, thus selecting cell subpopulations showing resistance to the different drugs." | 1.62 | Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line. ( Andreucci, E; Barbato, G; Biagioni, A; Cianchi, F; Coratti, F; Giovannelli, L; Magnelli, L; Papucci, L; Peri, S; Schiavone, N; Staderini, F; Versienti, G, 2021) |
| "Thalidomide (Thal) has been shown to increase the anti-tumor effect of chemotherapy agents in solid tumors." | 1.51 | Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin. ( Li, S; Liu, P; Shen, Y; Tian, Q; Wang, B; Wang, J; Wang, M; Wang, X; Yang, J, 2019) |
| "Lenalidomide is a type of immunomodulatory agent with anti-tumor activity by mainly expressed in the anti-angiogenesis." | 1.46 | Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor. ( Hu, S; Li, Z; Yan, H; Yuan, L, 2017) |
| "Thalidomide seems to be a promising agent that might bring about beneficial changes to the disarrangements of peripheral, hepatic, splanchnic and collateral systems in cirrhosis." | 1.43 | Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats. ( Alan, L; Hsieh, SL; Hsieh, YC; Huang, CC; Lee, KC; Lee, SD; Li, TH; Lin, HC; Tsai, CY; Yang, YY, 2016) |
| "Treatment with lenalidomide reduced tumor vessel density (p = 0." | 1.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "Lenalidomide is a novel analogue of thalidomide and has anti‑inflammatory, immunomodulatory and anti‑angiogenic effects." | 1.43 | Lenalidomide induces apoptosis and inhibits angiogenesis via caspase‑3 and VEGF in hepatocellular carcinoma cells. ( Ding, Y; Jiang, C; Qu, Z; Wu, J, 2016) |
| "Pheochromocytoma is a very rare tumor that stems from chromaffin cells and usually develops in the adrenal glands." | 1.42 | [Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments]. ( Bobrzyk, M; Chronowska, J; Kukla, U; Madej, P; Okopień, B; Łabuzek, K, 2015) |
| "Thalidomide, 2a and 2b were able to inhibit tumor growth (53." | 1.42 | Improvement of in vivo anticancer and antiangiogenic potential of thalidomide derivatives. ( Carvalho, AA; Cavalcanti, SM; da Costa, MP; da Costa, PM; de Araújo Viana, D; de Moraes, MO; de Oliveira Cardoso, MV; de Oliveira Filho, GB; Fechine-Jamacaru, FV; Ferreira, PM; Leite, AC; Pessoa, C, 2015) |
| "Thalidomide has demonstrated clinical activity in various malignancies affecting immunomodulatory and angiogenic pathways." | 1.42 | Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. ( Ambrozak, A; Barnett, S; Beedie, SL; Chau, CH; Figg, WD; Gardner, ER; Gütschow, M; Mahony, C; Peer, CJ; Pisle, S; Vargesson, N, 2015) |
| "Thalidomide precipitates were observed when its DMSO solution was added to the culture medium." | 1.42 | Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. ( Cheng, CC; Chiu, TH; Huang, YT; Lai, PC, 2015) |
| "Lenalidomide is an IMiD® immunomodulatory drug, which may warrant evaluation in urothelial carcinoma (UC)." | 1.40 | The preclinical activity of lenalidomide in indolent urothelial carcinoma. ( Jian, W; Lerner, SP; Levitt, JM; Sonpavde, G, 2014) |
| " The dosage of hemoglobin in sponge and in circulation was performed and the ratio between the values was tested using nonparametric Mann-Whitney test." | 1.39 | Standardization of a method to study angiogenesis in a mouse model. ( Azzalis, LA; Feder, CK; Feder, D; Fonseca, FL; Forsait, S; Junqueira, PE; Junqueira, VB; Pereira, EC; Perrazo, FF, 2013) |
| "Thalidomide has potent anti-inflammatory and anti-angiogenic properties." | 1.38 | Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. ( Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ, 2012) |
| "Thalidomide has proven to exert anti-inflammatory, anti-proliferative and anti-angiogenic activities in both neoplastic and non-neoplastic conditions." | 1.38 | Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. ( Alves Neves Diniz Ferreira, M; Cândida Araújo E Silva, A; da Silva Vieira, T; Dantas Cassali, G; Fonseca de Carvalho, L; Maria de Souza, C; Passos Andrade, S; Teresa Paz Lopes, M, 2012) |
| "Thalidomide was orally administered for 5 days." | 1.37 | Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model. ( Murata, K; Nitta, N; Nitta-Seko, A; Ohta, S; Otani, H; Sonoda, A; Takahashi, M; Tsuchiya, K, 2011) |
| "Quantification of tumor blood flow by using contrast-enhanced destruction-replenishment US shows the potential to guide drug dosage during antiangiogenic therapy." | 1.37 | Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US. ( Cao, LH; Han, F; Li, AH; Liu, JB; Liu, M; Luo, RZ; Zheng, W; Zhou, JH, 2011) |
| "Thalidomide has been used in the treatment of refractory Crohn's disease (CD), but the therapeutic mechanism is not defined." | 1.36 | Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). ( Binion, DG; Nelson, VM; Otterson, MF; Rafiee, P; Shaker, R; Stein, DJ, 2010) |
| "In the treatment of tumors with thalidomide, a rationale for its use is that it inhibits angiogenesis." | 1.35 | Thalidomide and thalidomide transformed by pH-dependent hydrolysis or by liver enzyme treatment does Not impede the proliferation of endothelial cells. ( Sandoval, FG; Shannon, EJ, 2008) |
| "Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by progressive anemia, massive splenomegaly, leukoerythroblastosis, extramedullary hematopoiesis and in about 50% of cases the presence of JAK2V617F mutation." | 1.35 | Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. ( Colagrande, M; Coletti, G; Di Ianni, M; Fargnoli, MC; Lapecorella, M; Moretti, L; Peris, K; Tabilio, A, 2009) |
| "Thalidomide has been shown to have anti-angiogenic effects in pre-clinical models as well as a significant antitumor effect in hematologic tumors." | 1.35 | Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis. ( Ge, JP; Yang, Y; Zhou, ZT, 2009) |
| "Treatment with Thalidomide preserved VV spatial density [2." | 1.35 | Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. ( Galili, O; Gössl, M; Herrmann, J; Lerman, A; Lerman, LO; Mannheim, D; Rajkumar, SV; Tang, H; Versari, D, 2009) |
| " Since thalidomide exhibits low oral bioavailability due to limitations in solubility, inclusion complexation using sulfobutyl ether-7 beta-cyclodextrin was used to improve the delivery of thalidomide." | 1.35 | Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice. ( Juvekar, A; Kale, R; Saraf, M; Tayade, P, 2008) |
| "Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis." | 1.34 | Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. ( Hisamori, S; Kadokawa, Y; Kubo, H; Mishima, M; Nakano, T; Tabata, C; Tabata, R; Takahashi, M, 2007) |
| "Attenuated inflammation and pathological angiogenesis achieved in hypercholesterolemia by thalidomide are accompanied by restoration of renovascular endothelial function but decreased basal renal hemodynamics." | 1.34 | Role of renal cortical neovascularization in experimental hypercholesterolemia. ( Chade, AR; Galili, O; Krier, JD; Lerman, A; Lerman, LO, 2007) |
| "Angiogenesis governs the progression of multiple myeloma (MM)." | 1.33 | Circulating endothelial progenitor cells in multiple myeloma: implications and significance. ( Akman, HO; Batuman, OA; Berenson, JR; Braunstein, M; Chen, L; Dai, K; Hussain, MM; Klueppelberg, U; Maroney, J; Norin, AJ; Ozçelik, T; Smith, EL; Vakil, V; Zhang, H, 2005) |
| "Treatment with thalidomide is a potentially useful antitumor therapy for ovarian cancer." | 1.33 | [Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice]. ( Cao, ZY; Li, W; Peng, ZL, 2005) |
| "Human cervical cancer cells (CaSki and SiHa) were injected into the flanks of nude mice." | 1.33 | Thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer. ( Downs, LS; Ramakrishnan, S; Rogers, LM; Yokoyama, Y, 2005) |
| "Thalidomide could inhibit tumor growth in a concentration-dependent manner in MCF-7 and HL-60; its IC50s for them were 18." | 1.33 | Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. ( Du, GJ; Lin, HH; Wang, MW; Xu, QT, 2005) |
| "Thalidomide was administered daily at doses ranging from 50 to 300 mg/kg by intraperitoneal injection." | 1.33 | Effect of thalidomide on colorectal cancer liver metastases in CBA mice. ( Christophi, C; Daruwalla, J; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2005) |
| "Thalidomide was begun at 50 mg, p." | 1.33 | Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. ( Anscher, MS; Clough, R; Crawford, J; Dewhirst, MW; Dunphy, F; Garst, J; Herndon, JE; Larrier, N; Marino, C; Marks, LB; Shafman, TD; Vujaskovic, Z; Zhou, S, 2006) |
| "Thalidomide is reported to be an anti-angiogenic agent, which is currently in phase II clinical trials for the treatment of advanced malignancies." | 1.32 | Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. ( Jiang, W; Li, QQ; Li, X; Liu, X; Liu, Y; Reed, E; Wang, J; Wang, Z; Zhang, Y, 2003) |
| "Thalidomide treatment did not significantly alter tumor growth as compared with controls." | 1.32 | Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. ( Beck, L; Frischer, JS; Huang, J; Kadenhe-Chiweshe, A; Kaicker, S; Kandel, JJ; McCrudden, KW; New, T; Serur, A; Yamashiro, DJ; Yokoi, A, 2003) |
| "Thalidomide cannot inhibit VEGF mRNA expression of grafted H22 tumor in mouse." | 1.32 | [Effect of thalidomide on tumor growth in mouse hepatoma H22 model]. ( Lu, ZJ; Zhai, Y, 2003) |
| "Thalidomide was found to demonstrate selective inhibition of androgen receptor positive LNCaP prostate cancer cells." | 1.32 | Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer. ( Brown, ML; Capitosti, SM; Hansen, TP, 2004) |
| "Thalidomide has demonstrated clinical activity in various malignancies including androgen-independent prostate cancer." | 1.32 | Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. ( Eger, K; Figg, WD; Gütschow, M; MacPherson, GR; Ng, SS, 2004) |
| "Clotrimazole was the most potent antiangiogenic compound and the agent capable of inhibiting tumor growth." | 1.32 | Differential effects of antiangiogenic compounds in neovascularization, leukocyte recruitment, VEGF production, and tumor growth in mice. ( Andrade, SP; Barcelos, LS; Belo, AV; Ferreira, MA; Teixeira, MM, 2004) |
| "Thalidomide was administered at daily doses increasing from 100 to 600 mg." | 1.31 | Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. ( Ascani, S; Baccarani, M; Finelli, C; Grafone, T; Isidori, A; Malagola, M; Martinelli, G; Piccaluga, PP; Pileri, SA; Ricci, P; Tura, S; Visani, G, 2002) |
| "Thalidomide is a teratogen with anti-angiogenic properties and causes stunted limb growth (dysmelia) during human embryogenesis." | 1.31 | Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. ( Günther, J; Hescheler, J; Sauer, H; Wartenberg, M, 2000) |
| "Thalidomide failed to inhibit the growth of xenograft tumours." | 1.31 | Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide. ( Douglas, ML; Hii, SI; Jonsson, JR; Nicol, DL; Reid, JL, 2002) |
| " Additionally, we investigated a potential enhancement of the antitumoral action of thalidomide when combined with a low dose of the antineoplastic carmustine." | 1.31 | Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma. ( Arrieta, O; Guevara, P; Rembao, D; Rivera, E; Sotelo, J; Tamariz, J, 2002) |
| "Thalidomide has been shown to be an inhibitor of angiogenesis in a rabbit cornea micropocket model; however, it has failed to demonstrate this activity in other models." | 1.30 | Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. ( Bauer, KS; Dixon, SC; Figg, WD, 1998) |
| "Oral treatment of thalidomide or sulindac alone inhibited tumour growth by 55% and 35% respectively." | 1.30 | Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. ( D'Amato, RJ; Panigrahy, D; Verheul, HM; Yuan, J, 1999) |
| "Thalidomide has been previously shown to inhibit angiogenesis induced by basic fibroblast growth factor in vivo, using the rabbit corneal micropocket assay." | 1.30 | Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. ( Friedlander, DR; Kaplan, G; Moreira, AL; Shif, B; Zagzag, D, 1999) |
| "Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans." | 1.29 | Thalidomide is an inhibitor of angiogenesis. ( D'Amato, RJ; Flynn, E; Folkman, J; Loughnan, MS, 1994) |
| "Thalidomide has recently been shown to antagonize basic fibroblast growth factor-induced angiogenesis in the rat corneal micropocket assay." | 1.29 | The effect of thalidomide on experimental tumors and metastases. ( Clow, KA; Fryer, KH; Hayes, MM; Minchinton, AI; Wendt, KR, 1996) |
| "The patient had a recurrence of the choroidal neovascular membrane eight months after the start of thalidomide therapy." | 1.29 | Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. ( Gorin, MB; Ip, M, 1996) |
| "Thalidomide trials have been slow to recruit, therefore buyers clubs are working to make the drug available through their services." | 1.29 | Thalidomide and HIV: several possible uses. ( Smith, D, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (9.79) | 18.2507 |
| 2000's | 145 (61.70) | 29.6817 |
| 2010's | 60 (25.53) | 24.3611 |
| 2020's | 7 (2.98) | 2.80 |
| Authors | Studies |
|---|---|
| Contino-Pépin, C | 1 |
| Parat, A | 1 |
| Périno, S | 1 |
| Lenoir, C | 1 |
| Vidal, M | 1 |
| Galons, H | 1 |
| Karlik, S | 1 |
| Pucci, B | 1 |
| Xia, Y | 1 |
| Wang, WC | 1 |
| Shen, WH | 1 |
| Xu, K | 1 |
| Hu, YY | 1 |
| Han, GH | 1 |
| Liu, YB | 1 |
| Nathan, J | 1 |
| Shameera, R | 1 |
| Palanivel, G | 1 |
| Goleh, Z | 3 |
| Mokhtari-Dizaji, M | 3 |
| Toliyat, T | 3 |
| Shen, Y | 3 |
| Li, S | 2 |
| Wang, X | 4 |
| Wang, M | 1 |
| Tian, Q | 1 |
| Yang, J | 6 |
| Wang, J | 2 |
| Wang, B | 1 |
| Liu, P | 1 |
| Tang, CT | 1 |
| Zhang, QW | 1 |
| Wu, S | 1 |
| Tang, MY | 1 |
| Liang, Q | 1 |
| Lin, XL | 1 |
| Gao, YJ | 1 |
| Ge, ZZ | 1 |
| MengLv, L | 1 |
| Zhang, X | 4 |
| Wang, F | 3 |
| Wang, L | 1 |
| Wang, S | 2 |
| Xue, A | 1 |
| Shi, J | 1 |
| Zheng, C | 1 |
| Huang, Y | 2 |
| Peri, S | 1 |
| Biagioni, A | 1 |
| Versienti, G | 1 |
| Andreucci, E | 1 |
| Staderini, F | 1 |
| Barbato, G | 1 |
| Giovannelli, L | 1 |
| Coratti, F | 1 |
| Schiavone, N | 1 |
| Cianchi, F | 1 |
| Papucci, L | 1 |
| Magnelli, L | 1 |
| Wang, Y | 2 |
| Xu, J | 1 |
| Wang, C | 1 |
| Dai, K | 2 |
| Knobloch, J | 1 |
| Jungck, D | 1 |
| Koch, A | 1 |
| Mercurio, A | 1 |
| Adriani, G | 1 |
| Catalano, A | 1 |
| Carocci, A | 1 |
| Rao, L | 1 |
| Lentini, G | 1 |
| Cavalluzzi, MM | 1 |
| Franchini, C | 1 |
| Vacca, A | 6 |
| Corbo, F | 1 |
| Hu, S | 1 |
| Yuan, L | 1 |
| Yan, H | 1 |
| Li, Z | 1 |
| Tokunaga, E | 1 |
| Akiyama, H | 1 |
| Soloshonok, VA | 1 |
| Inoue, Y | 1 |
| Hara, H | 1 |
| Shibata, N | 1 |
| Veeriah, V | 1 |
| Kumar, P | 1 |
| Sundaresan, L | 1 |
| Mafitha, Z | 1 |
| Gupta, R | 1 |
| Saran, U | 1 |
| Manivannan, J | 1 |
| Chatterjee, S | 1 |
| Liu, JH | 1 |
| Wu, HH | 1 |
| Zhao, YK | 1 |
| Gao, Q | 1 |
| Luo, DQ | 1 |
| Guo, HM | 1 |
| Sun, L | 1 |
| Yang, L | 1 |
| Liu, XJ | 1 |
| Nie, ZY | 1 |
| Luo, JM | 1 |
| Mohammadi Kian, M | 1 |
| Mohammadi, S | 1 |
| Tavallaei, M | 1 |
| Chahardouli, B | 1 |
| Rostami, S | 1 |
| Zahedpanah, M | 1 |
| Ghavamzadeh, A | 1 |
| Nikbakht, M | 1 |
| Łączkowski, KZ | 1 |
| Baranowska-Łączkowska, A | 1 |
| Ionov, ID | 1 |
| Gorev, NP | 1 |
| Roslavtseva, LA | 1 |
| Frenkel, DD | 1 |
| Piechnik, A | 1 |
| Dmoszynska, A | 3 |
| Omiotek, M | 1 |
| Mlak, R | 1 |
| Kowal, M | 1 |
| Stilgenbauer, S | 1 |
| Bullinger, L | 1 |
| Giannopoulos, K | 1 |
| Lacout, A | 1 |
| Marcy, PY | 1 |
| El Hajjam, M | 1 |
| Lacombe, P | 1 |
| Robison, NJ | 1 |
| Campigotto, F | 1 |
| Chi, SN | 1 |
| Manley, PE | 1 |
| Turner, CD | 1 |
| Zimmerman, MA | 1 |
| Chordas, CA | 1 |
| Werger, AM | 1 |
| Allen, JC | 1 |
| Goldman, S | 1 |
| Rubin, JB | 1 |
| Isakoff, MS | 1 |
| Pan, WJ | 1 |
| Khatib, ZA | 1 |
| Comito, MA | 1 |
| Bendel, AE | 1 |
| Pietrantonio, JB | 1 |
| Kondrat, L | 1 |
| Hubbs, SM | 1 |
| Neuberg, DS | 1 |
| Kieran, MW | 1 |
| Ria, R | 4 |
| Catacchio, I | 1 |
| Berardi, S | 2 |
| De Luisi, A | 2 |
| Caivano, A | 2 |
| Piccoli, C | 1 |
| Ruggieri, V | 1 |
| Frassanito, MA | 1 |
| Ribatti, D | 5 |
| Nico, B | 3 |
| Annese, T | 1 |
| Ruggieri, S | 1 |
| Guarini, A | 2 |
| Minoia, C | 1 |
| Ditonno, P | 2 |
| Angelucci, E | 1 |
| Derudas, D | 1 |
| Moschetta, M | 2 |
| Dammacco, F | 3 |
| Feder, D | 1 |
| Perrazo, FF | 1 |
| Pereira, EC | 1 |
| Forsait, S | 1 |
| Feder, CK | 1 |
| Junqueira, PE | 1 |
| Junqueira, VB | 1 |
| Azzalis, LA | 1 |
| Fonseca, FL | 1 |
| Yung, R | 1 |
| Seyfoddin, V | 1 |
| Guise, C | 1 |
| Tijono, S | 1 |
| McGregor, A | 1 |
| Connor, B | 1 |
| Ching, LM | 1 |
| Kampschulte, M | 1 |
| Gunkel, I | 1 |
| Stieger, P | 1 |
| Sedding, DG | 1 |
| Brinkmann, A | 1 |
| Ritman, EL | 1 |
| Krombach, GA | 1 |
| Langheinrich, AC | 1 |
| Buckstein, R | 1 |
| Kerbel, R | 2 |
| Cheung, M | 1 |
| Shaked, Y | 1 |
| Chodirker, L | 1 |
| Lee, CR | 1 |
| Lenis, M | 1 |
| Davidson, C | 1 |
| Cussen, MA | 1 |
| Reis, M | 1 |
| Chesney, A | 1 |
| Zhang, L | 1 |
| Mamedov, A | 1 |
| Wells, RA | 1 |
| El-Aarag, BY | 1 |
| Kasai, T | 1 |
| Zahran, MA | 1 |
| Zakhary, NI | 1 |
| Shigehiro, T | 1 |
| Sekhar, SC | 1 |
| Agwa, HS | 1 |
| Mizutani, A | 1 |
| Murakami, H | 1 |
| Kakuta, H | 1 |
| Seno, M | 1 |
| Molinari, AJ | 2 |
| Thorp, SI | 1 |
| Portu, AM | 1 |
| Saint Martin, G | 1 |
| Pozzi, EC | 2 |
| Heber, EM | 2 |
| Bortolussi, S | 1 |
| Itoiz, ME | 2 |
| Aromando, RF | 2 |
| Monti Hughes, A | 2 |
| Garabalino, MA | 2 |
| Altieri, S | 1 |
| Trivillin, VA | 2 |
| Schwint, AE | 2 |
| Jian, W | 1 |
| Levitt, JM | 1 |
| Lerner, SP | 1 |
| Sonpavde, G | 1 |
| Liu, J | 1 |
| Yang, X | 1 |
| Yan, Q | 1 |
| Han, W | 1 |
| Kukla, U | 1 |
| Łabuzek, K | 1 |
| Chronowska, J | 1 |
| Bobrzyk, M | 1 |
| Madej, P | 1 |
| Okopień, B | 1 |
| Pereira, BG | 1 |
| Batista, LF | 1 |
| de Souza, PA | 1 |
| da Silva, GR | 1 |
| Andrade, SP | 3 |
| Serakides, R | 1 |
| da Nova Mussel, W | 1 |
| Silva-Cunha, A | 1 |
| Fialho, SL | 1 |
| da Costa, PM | 1 |
| da Costa, MP | 1 |
| Carvalho, AA | 1 |
| Cavalcanti, SM | 1 |
| de Oliveira Cardoso, MV | 1 |
| de Oliveira Filho, GB | 1 |
| de Araújo Viana, D | 1 |
| Fechine-Jamacaru, FV | 1 |
| Leite, AC | 1 |
| de Moraes, MO | 1 |
| Pessoa, C | 1 |
| Ferreira, PM | 1 |
| Behl, T | 1 |
| Kaur, I | 1 |
| Goel, H | 1 |
| Kotwani, A | 1 |
| Beedie, SL | 1 |
| Peer, CJ | 1 |
| Pisle, S | 1 |
| Gardner, ER | 1 |
| Mahony, C | 1 |
| Barnett, S | 1 |
| Ambrozak, A | 1 |
| Gütschow, M | 2 |
| Chau, CH | 1 |
| Vargesson, N | 1 |
| Figg, WD | 6 |
| Huang, YT | 1 |
| Cheng, CC | 1 |
| Chiu, TH | 1 |
| Lai, PC | 1 |
| Li, TH | 1 |
| Huang, CC | 2 |
| Yang, YY | 1 |
| Lee, KC | 1 |
| Hsieh, SL | 1 |
| Hsieh, YC | 1 |
| Alan, L | 1 |
| Lin, HC | 1 |
| Lee, SD | 1 |
| Tsai, CY | 1 |
| Shimizu, T | 1 |
| Kurozumi, K | 2 |
| Ishida, J | 1 |
| Ichikawa, T | 2 |
| Date, I | 2 |
| Leuci, V | 1 |
| Maione, F | 1 |
| Rotolo, R | 1 |
| Giraudo, E | 1 |
| Sassi, F | 1 |
| Migliardi, G | 1 |
| Todorovic, M | 1 |
| Gammaitoni, L | 1 |
| Mesiano, G | 1 |
| Giraudo, L | 1 |
| Luraghi, P | 1 |
| Leone, F | 1 |
| Bussolino, F | 1 |
| Grignani, G | 1 |
| Aglietta, M | 1 |
| Trusolino, L | 1 |
| Bertotti, A | 1 |
| Sangiolo, D | 1 |
| Lv, M | 1 |
| Qu, Z | 1 |
| Jiang, C | 1 |
| Wu, J | 1 |
| Ding, Y | 1 |
| Sanchez, E | 1 |
| Li, M | 1 |
| Wang, CS | 1 |
| Tang, G | 1 |
| Gillespie, A | 1 |
| Chen, H | 1 |
| Berenson, JR | 3 |
| Misawa, S | 1 |
| Shannon, EJ | 1 |
| Sandoval, FG | 1 |
| Kassam, A | 1 |
| Mandel, K | 1 |
| Lu, L | 1 |
| Payvandi, F | 2 |
| Wu, L | 1 |
| Zhang, LH | 1 |
| Hariri, RJ | 1 |
| Man, HW | 2 |
| Chen, RS | 1 |
| Muller, GW | 3 |
| Hughes, CC | 1 |
| Stirling, DI | 3 |
| Schafer, PH | 3 |
| Bartlett, JB | 1 |
| Khakoo, AY | 1 |
| Sidman, RL | 1 |
| Pasqualini, R | 1 |
| Arap, W | 1 |
| Colagrande, M | 1 |
| Di Ianni, M | 1 |
| Coletti, G | 1 |
| Peris, K | 1 |
| Fargnoli, MC | 1 |
| Moretti, L | 1 |
| Lapecorella, M | 1 |
| Tabilio, A | 2 |
| Bielenberg, DR | 1 |
| D'Amore, PA | 1 |
| Yang, Y | 1 |
| Ge, JP | 1 |
| Zhou, ZT | 1 |
| Liu, Y | 2 |
| Li, H | 1 |
| Matsui, O | 1 |
| Gössl, M | 1 |
| Herrmann, J | 1 |
| Tang, H | 1 |
| Versari, D | 1 |
| Galili, O | 2 |
| Mannheim, D | 1 |
| Rajkumar, SV | 7 |
| Lerman, LO | 2 |
| Lerman, A | 2 |
| Ryu, JK | 1 |
| Jantaratnotai, N | 1 |
| McLarnon, JG | 1 |
| Kotla, V | 1 |
| Goel, S | 1 |
| Nischal, S | 1 |
| Heuck, C | 1 |
| Vivek, K | 1 |
| Das, B | 1 |
| Verma, A | 1 |
| Zangari, M | 3 |
| Fink, LM | 1 |
| Elice, F | 1 |
| Zhan, F | 1 |
| Adcock, DM | 1 |
| Tricot, GJ | 1 |
| Rafiee, P | 1 |
| Stein, DJ | 1 |
| Nelson, VM | 1 |
| Otterson, MF | 1 |
| Shaker, R | 1 |
| Binion, DG | 1 |
| Lacy, MQ | 2 |
| Reck, M | 1 |
| Gatzemeier, U | 1 |
| Ruan, J | 1 |
| Martin, P | 1 |
| Coleman, M | 1 |
| Furman, RR | 1 |
| Cheung, K | 1 |
| Faye, A | 1 |
| Elstrom, R | 1 |
| Lachs, M | 1 |
| Hajjar, KA | 1 |
| Leonard, JP | 1 |
| Oh, ST | 1 |
| Gotlib, J | 1 |
| Zhang, Y | 2 |
| Zhang, H | 3 |
| Chen, J | 1 |
| Zhao, H | 1 |
| Zeng, X | 1 |
| Qing, C | 1 |
| Biemond, BJ | 1 |
| Nitta-Seko, A | 1 |
| Nitta, N | 1 |
| Sonoda, A | 1 |
| Otani, H | 1 |
| Tsuchiya, K | 1 |
| Ohta, S | 1 |
| Takahashi, M | 2 |
| Murata, K | 1 |
| Onishi, M | 1 |
| Zhou, JH | 1 |
| Cao, LH | 1 |
| Liu, JB | 1 |
| Zheng, W | 1 |
| Liu, M | 1 |
| Luo, RZ | 1 |
| Han, F | 1 |
| Li, AH | 1 |
| Ferrucci, A | 1 |
| Coluccia, AM | 1 |
| de Luca, E | 1 |
| Pieroni, L | 1 |
| Maffia, M | 1 |
| Urbani, A | 1 |
| Di Pietro, G | 1 |
| Ranieri, G | 1 |
| Basile, A | 1 |
| Cascavilla, N | 1 |
| Capalbo, S | 1 |
| Quarta, G | 1 |
| Muthuramalingam, SR | 1 |
| Braybrooke, JP | 1 |
| Blann, AD | 1 |
| Madhusudan, S | 1 |
| Wilner, S | 1 |
| Jenkins, A | 1 |
| Han, C | 1 |
| Kaur, K | 1 |
| Perren, T | 1 |
| Ganesan, TS | 1 |
| Mabeta, P | 1 |
| Pepper, MS | 1 |
| Podar, K | 3 |
| Anderson, KC | 4 |
| Cheng, J | 1 |
| Gu, YJ | 1 |
| Cheng, SH | 1 |
| Wong, WT | 1 |
| Wellbrock, J | 1 |
| Fiedler, W | 1 |
| Aguayo, A | 2 |
| Armillas-Canseco, FM | 1 |
| Martínez-Baños, D | 1 |
| Zaja, F | 1 |
| De Luca, S | 1 |
| Vitolo, U | 1 |
| Orsucci, L | 1 |
| Levis, A | 1 |
| Salvi, F | 1 |
| Rusconi, C | 1 |
| Ravelli, E | 1 |
| Tucci, A | 1 |
| Bottelli, C | 1 |
| Balzarotti, M | 1 |
| Brusamolino, E | 1 |
| Bonfichi, M | 1 |
| Pileri, SA | 2 |
| Sabattini, E | 1 |
| Volpetti, S | 1 |
| Monagheddu, C | 1 |
| Fanin, R | 1 |
| Shao, YY | 1 |
| Lin, ZZ | 1 |
| Hsu, C | 2 |
| Lee, KD | 1 |
| Hsiao, CH | 1 |
| Lu, YS | 1 |
| Shen, YC | 1 |
| Hsu, CH | 1 |
| Cheng, AL | 2 |
| Ito, T | 1 |
| Handa, H | 1 |
| Young, RJ | 1 |
| Tin, AW | 1 |
| Brown, NJ | 1 |
| Jitlal, M | 1 |
| Lee, SM | 2 |
| Woll, PJ | 1 |
| Stewart, EE | 1 |
| Sun, H | 1 |
| Chen, X | 1 |
| Chen, Y | 1 |
| Garcia, BM | 1 |
| Lee, TY | 1 |
| Maria de Souza, C | 1 |
| Fonseca de Carvalho, L | 1 |
| da Silva Vieira, T | 1 |
| Cândida Araújo E Silva, A | 1 |
| Teresa Paz Lopes, M | 1 |
| Alves Neves Diniz Ferreira, M | 1 |
| Passos Andrade, S | 1 |
| Dantas Cassali, G | 1 |
| Nigg, DW | 1 |
| Chauhan, D | 2 |
| Tian, Z | 1 |
| Nicholson, B | 1 |
| Kumar, KG | 1 |
| Zhou, B | 1 |
| Carrasco, R | 1 |
| McDermott, JL | 1 |
| Leach, CA | 1 |
| Fulcinniti, M | 1 |
| Kodrasov, MP | 1 |
| Weinstock, J | 1 |
| Kingsbury, WD | 1 |
| Hideshima, T | 3 |
| Shah, PK | 1 |
| Minvielle, S | 1 |
| Altun, M | 1 |
| Kessler, BM | 1 |
| Orlowski, R | 1 |
| Richardson, P | 2 |
| Munshi, N | 1 |
| Ng, SS | 2 |
| Brown, M | 1 |
| Rupnick, MA | 1 |
| Panigrahy, D | 2 |
| Zhang, CY | 1 |
| Dallabrida, SM | 1 |
| Lowell, BB | 1 |
| Langer, R | 1 |
| Folkman, MJ | 1 |
| Cool, RM | 1 |
| Herrington, JD | 1 |
| Piccaluga, PP | 1 |
| Visani, G | 1 |
| Ascani, S | 1 |
| Grafone, T | 1 |
| Isidori, A | 1 |
| Malagola, M | 1 |
| Finelli, C | 1 |
| Martinelli, G | 1 |
| Ricci, P | 1 |
| Baccarani, M | 1 |
| Tura, S | 2 |
| Friedrich, MJ | 1 |
| Folkman, J | 4 |
| Yaccoby, S | 1 |
| Johnson, CL | 1 |
| Mahaffey, SC | 1 |
| Wezeman, MJ | 1 |
| Barlogie, B | 1 |
| Epstein, J | 1 |
| Lentzsch, S | 1 |
| LeBlanc, R | 1 |
| Davies, F | 1 |
| Lin, B | 1 |
| Catley, L | 1 |
| Hattori, Y | 3 |
| Augustin, HG | 1 |
| Cortes, J | 2 |
| Kantarjian, H | 2 |
| Albitar, M | 3 |
| Thomas, D | 2 |
| Faderl, S | 3 |
| Koller, C | 1 |
| Garcia-Manero, G | 3 |
| Giles, F | 2 |
| Andreeff, M | 1 |
| O'Brien, S | 1 |
| Keating, M | 1 |
| Estey, E | 1 |
| Meierhofer, C | 1 |
| Wiedermann, CJ | 1 |
| Bauer, JA | 1 |
| Morrison, BH | 1 |
| Grane, RW | 1 |
| Jacobs, BS | 1 |
| Borden, EC | 1 |
| Lindner, DJ | 1 |
| Dolev, E | 1 |
| Eisenkraft, A | 1 |
| Luria, S | 1 |
| Robenshtok, E | 1 |
| Hourvitz, A | 1 |
| Li, X | 1 |
| Liu, X | 1 |
| Wang, Z | 1 |
| Jiang, W | 1 |
| Reed, E | 2 |
| Li, QQ | 1 |
| Semeraro, F | 1 |
| Merchionne, F | 1 |
| Coluccia, M | 1 |
| Boccarelli, A | 1 |
| Scavelli, C | 2 |
| Gernone, A | 1 |
| Battelli, F | 1 |
| Guidolin, D | 1 |
| Petrucci, MT | 1 |
| Dudek, AZ | 1 |
| Pawlak, WZ | 1 |
| Kirstein, MN | 1 |
| Thompson, MA | 1 |
| Witzig, TE | 3 |
| Kumar, S | 3 |
| Timm, MM | 1 |
| Haug, J | 1 |
| Fonseca, R | 2 |
| Greipp, PR | 2 |
| Lust, JA | 2 |
| Gelati, M | 1 |
| Corsini, E | 1 |
| Frigerio, S | 1 |
| Pollo, B | 1 |
| Broggi, G | 1 |
| Croci, D | 1 |
| Silvani, A | 1 |
| Boiardi, A | 1 |
| Salmaggi, A | 1 |
| Steins, MB | 2 |
| Bieker, R | 3 |
| Padró, T | 3 |
| Kessler, T | 3 |
| Kienast, J | 3 |
| Berdel, WE | 3 |
| Mesters, RM | 3 |
| Kaicker, S | 1 |
| McCrudden, KW | 1 |
| Beck, L | 1 |
| New, T | 1 |
| Huang, J | 1 |
| Frischer, JS | 1 |
| Serur, A | 1 |
| Kadenhe-Chiweshe, A | 1 |
| Yokoi, A | 1 |
| Kandel, JJ | 1 |
| Yamashiro, DJ | 1 |
| Gee, MS | 1 |
| Makonnen, S | 1 |
| al-Kofahi, K | 1 |
| Roysam, B | 1 |
| Lee, WM | 1 |
| Zhai, Y | 1 |
| Lu, ZJ | 1 |
| Capitosti, SM | 1 |
| Hansen, TP | 1 |
| Brown, ML | 2 |
| Anaissie, E | 1 |
| Stopeck, A | 1 |
| Morimoto, A | 1 |
| Tan, N | 1 |
| Lancet, J | 1 |
| Cooper, M | 1 |
| Hannah, A | 1 |
| Cherrington, J | 1 |
| Giles, FJ | 2 |
| Dispenzieri, A | 1 |
| Wellik, LE | 1 |
| Gertz, MA | 1 |
| Kyle, RA | 2 |
| Sparano, JA | 1 |
| Gray, R | 1 |
| Giantonio, B | 1 |
| O'Dwyer, P | 1 |
| Comis, RL | 1 |
| Moehler, TM | 2 |
| Hillengass, J | 2 |
| Goldschmidt, H | 2 |
| Ho, AD | 1 |
| Du, W | 1 |
| Hashiguchi, A | 1 |
| Kondoh, K | 1 |
| Hozumi, N | 1 |
| Ikeda, Y | 1 |
| Sakamoto, M | 1 |
| Hata, J | 1 |
| Yamada, T | 1 |
| Bressoud, A | 1 |
| Schwab, BZ | 1 |
| Akaza, H | 1 |
| Nakagawa, M | 1 |
| Tsuruo, T | 1 |
| Saijo, N | 1 |
| Sone, S | 1 |
| Yamamoto, N | 1 |
| Kakeji, Y | 1 |
| Nakamura, S | 2 |
| Kurebayashi, J | 1 |
| Isonishi, S | 1 |
| Ohashi, Y | 1 |
| Blackledge, G | 1 |
| Carmichael, J | 1 |
| Liu, WM | 1 |
| Strauss, SJ | 1 |
| Chaplin, T | 1 |
| Shahin, S | 1 |
| Propper, DJ | 1 |
| Young, BD | 1 |
| Joel, SP | 1 |
| Malpas, JS | 1 |
| MacPherson, GR | 1 |
| Eger, K | 1 |
| Bruno, B | 1 |
| Rotta, M | 1 |
| Giaccone, L | 1 |
| Massaia, M | 1 |
| Bertola, A | 1 |
| Palumbo, A | 1 |
| Boccadoro, M | 1 |
| Brennen, WN | 1 |
| Cooper, CR | 1 |
| Capitosti, S | 1 |
| Sikes, RA | 1 |
| Sengupta, S | 1 |
| Kiziltepe, T | 1 |
| Sasisekharan, R | 1 |
| Reiriz, AB | 1 |
| Richter, MF | 1 |
| Fernandes, S | 1 |
| Cancela, AI | 1 |
| Costa, TD | 1 |
| Di Leone, LP | 1 |
| Schwartsmann, G | 1 |
| Belo, AV | 2 |
| Barcelos, LS | 1 |
| Teixeira, MM | 1 |
| Ferreira, MA | 2 |
| Roccaro, AM | 1 |
| Crivellato, E | 1 |
| Vakil, V | 1 |
| Braunstein, M | 1 |
| Smith, EL | 1 |
| Maroney, J | 1 |
| Chen, L | 1 |
| Hussain, MM | 1 |
| Klueppelberg, U | 1 |
| Norin, AJ | 1 |
| Akman, HO | 1 |
| Ozçelik, T | 1 |
| Batuman, OA | 1 |
| Arora, B | 1 |
| Mesa, R | 1 |
| Tefferi, A | 2 |
| Zhang, ZL | 2 |
| Liu, ZS | 2 |
| Sun, Q | 2 |
| Pagnucco, G | 1 |
| Cardinale, G | 1 |
| Gervasi, F | 1 |
| Ponzoni, M | 1 |
| Collins, TS | 1 |
| Hurwitz, HI | 1 |
| Ozkan, M | 1 |
| Eser, B | 1 |
| Er, O | 1 |
| Dogu, GG | 1 |
| Altinbas, M | 1 |
| Podhorecka, M | 1 |
| Manko, J | 1 |
| Bojarska-Junak, A | 2 |
| Rolinski, J | 2 |
| Skomra, D | 1 |
| Li, W | 1 |
| Peng, ZL | 1 |
| Cao, ZY | 1 |
| Tsuneki, H | 1 |
| Ma, EL | 1 |
| Kobayashi, S | 1 |
| Sekizaki, N | 1 |
| Maekawa, K | 1 |
| Sasaoka, T | 1 |
| Wang, MW | 2 |
| Kimura, I | 1 |
| Chen, CN | 1 |
| Chen, LT | 1 |
| Wu, CY | 1 |
| Hsieh, FJ | 1 |
| Downs, LS | 1 |
| Rogers, LM | 1 |
| Yokoyama, Y | 1 |
| Ramakrishnan, S | 1 |
| Du, GJ | 1 |
| Lin, HH | 1 |
| Xu, QT | 1 |
| Hatjiharissi, E | 1 |
| Terpos, E | 1 |
| Papaioannou, M | 1 |
| Hatjileontis, C | 1 |
| Kaloutsi, V | 1 |
| Galaktidou, G | 1 |
| Gerotziafas, G | 1 |
| Christakis, J | 1 |
| Zervas, K | 1 |
| Raza, A | 1 |
| Qawi, H | 1 |
| Mehdi, M | 1 |
| Mumtaz, M | 1 |
| Galili, N | 1 |
| Daruwalla, J | 1 |
| Nikfarjam, M | 1 |
| Malcontenti-Wilson, C | 1 |
| Muralidharan, V | 1 |
| Christophi, C | 1 |
| Takano, S | 1 |
| Crane, E | 1 |
| List, A | 2 |
| Son, MJ | 1 |
| Kim, JS | 1 |
| Kim, MH | 1 |
| Song, HS | 1 |
| Kim, JT | 1 |
| Kim, H | 1 |
| Shin, T | 1 |
| Jeon, HJ | 1 |
| Lee, DS | 1 |
| Park, SY | 1 |
| Kim, YJ | 1 |
| Kim, JH | 1 |
| Nam, DH | 1 |
| Bouscary, D | 1 |
| Legros, L | 1 |
| Tulliez, M | 1 |
| Dubois, S | 1 |
| Mahe, B | 1 |
| Beyne-Rauzy, O | 1 |
| Quarre, MC | 1 |
| Vassilief, D | 1 |
| Varet, B | 1 |
| Aouba, A | 1 |
| Gardembas, M | 1 |
| Giraudier, S | 1 |
| Guerci, A | 1 |
| Rousselot, P | 1 |
| Gaillard, F | 1 |
| Moreau, A | 1 |
| Rousselet, MC | 1 |
| Ifrah, N | 1 |
| Fenaux, P | 1 |
| Dreyfus, F | 1 |
| Bertolotto, M | 1 |
| Pozzato, G | 2 |
| Crocè, LS | 1 |
| Nascimben, F | 2 |
| Gasparini, C | 1 |
| Cova, MA | 1 |
| Tiribelli, C | 1 |
| Segers, J | 1 |
| Di Fazio, V | 1 |
| Ansiaux, R | 1 |
| Martinive, P | 1 |
| Feron, O | 1 |
| Wallemacq, P | 1 |
| Gallez, B | 1 |
| Kim, DH | 1 |
| Choe, YS | 1 |
| Jung, KH | 1 |
| Lee, KH | 1 |
| Choi, Y | 1 |
| Kim, BT | 1 |
| Thomas, DA | 1 |
| Cortes, JE | 1 |
| Verstovsek, S | 2 |
| O'Brien, SM | 1 |
| Keating, MJ | 1 |
| Pierce, S | 1 |
| Zeldis, J | 1 |
| Kantarjian, HM | 2 |
| Mesa, RA | 1 |
| Lasho, TL | 1 |
| Hogan, WJ | 1 |
| Litzow, MR | 1 |
| Allred, JB | 1 |
| Jones, D | 1 |
| Byrne, C | 1 |
| Zeldis, JB | 2 |
| Ketterling, RP | 1 |
| McClure, RF | 1 |
| Balasubramanian, L | 1 |
| Evens, AM | 1 |
| Stepień, H | 1 |
| Lawnicka, H | 1 |
| Mucha, S | 1 |
| Wagrowska-Danilewicz, M | 1 |
| Stepień, B | 1 |
| Siejka, A | 1 |
| Komorowski, J | 1 |
| Sze, DM | 1 |
| Brown, R | 1 |
| Yang, S | 1 |
| Ho, PJ | 1 |
| Gibson, J | 1 |
| Joshua, D | 1 |
| Chon, HS | 1 |
| Hu, W | 1 |
| Kavanagh, JJ | 1 |
| Anscher, MS | 1 |
| Garst, J | 1 |
| Marks, LB | 1 |
| Larrier, N | 1 |
| Dunphy, F | 1 |
| Herndon, JE | 1 |
| Clough, R | 1 |
| Marino, C | 1 |
| Vujaskovic, Z | 1 |
| Zhou, S | 1 |
| Dewhirst, MW | 1 |
| Shafman, TD | 1 |
| Crawford, J | 1 |
| Usnarska-Zubkiewicz, L | 1 |
| Poreba, M | 1 |
| Kuliczkowski, K | 1 |
| Shalapour, S | 1 |
| Zelmer, A | 1 |
| Pfau, M | 1 |
| Moderegger, E | 1 |
| Costa-Blechschmidt, C | 1 |
| van Landeghem, FK | 1 |
| Taube, T | 1 |
| Fichtner, I | 1 |
| Bührer, C | 1 |
| Henze, G | 1 |
| Seeger, K | 1 |
| Wellmann, S | 1 |
| Chidlow, JH | 1 |
| Langston, W | 1 |
| Greer, JJ | 1 |
| Ostanin, D | 1 |
| Abdelbaqi, M | 1 |
| Houghton, J | 1 |
| Senthilkumar, A | 1 |
| Shukla, D | 1 |
| Mazar, AP | 1 |
| Grisham, MB | 1 |
| Kevil, CG | 1 |
| Kirchmair, R | 1 |
| Tietz, AB | 1 |
| Panagiotou, E | 1 |
| Walter, DH | 1 |
| Silver, M | 1 |
| Yoon, YS | 1 |
| Schratzberger, P | 1 |
| Weber, A | 1 |
| Kusano, K | 1 |
| Weinberg, DH | 1 |
| Ropper, AH | 1 |
| Isner, JM | 1 |
| Losordo, DW | 1 |
| Glasmacher, A | 1 |
| McMeekin, DS | 2 |
| Sill, MW | 2 |
| Benbrook, D | 2 |
| Darcy, KM | 2 |
| Stearns-Kurosawa, DJ | 2 |
| Eaton, L | 1 |
| Yamada, SD | 1 |
| Melchert, M | 1 |
| Kesari, S | 1 |
| Schiff, D | 1 |
| Doherty, L | 1 |
| Gigas, DC | 1 |
| Batchelor, TT | 1 |
| Muzikansky, A | 1 |
| O'Neill, A | 1 |
| Drappatz, J | 1 |
| Chen-Plotkin, AS | 1 |
| Ramakrishna, N | 1 |
| Weiss, SE | 1 |
| Levy, B | 1 |
| Bradshaw, J | 1 |
| Kracher, J | 1 |
| Laforme, A | 1 |
| Black, PM | 1 |
| Kieran, M | 1 |
| Wen, PY | 1 |
| Ma, WW | 1 |
| Jimeno, A | 1 |
| Tabata, C | 1 |
| Tabata, R | 1 |
| Kadokawa, Y | 1 |
| Hisamori, S | 1 |
| Mishima, M | 1 |
| Nakano, T | 1 |
| Kubo, H | 1 |
| Webster, K | 1 |
| Waggoner, S | 1 |
| Chade, AR | 1 |
| Krier, JD | 1 |
| Mangiameli, DP | 1 |
| Blansfield, JA | 2 |
| Kachala, S | 1 |
| Lorang, D | 2 |
| Libutti, SK | 2 |
| Mileshkin, L | 1 |
| Honemann, D | 1 |
| Gambell, P | 1 |
| Trivett, M | 1 |
| Hayakawa, Y | 1 |
| Smyth, M | 1 |
| Beshay, V | 1 |
| Ritchie, D | 1 |
| Simmons, P | 1 |
| Milner, AD | 1 |
| Prince, HM | 1 |
| Pérol, M | 1 |
| Arpin, D | 1 |
| Bachelot, T | 1 |
| Ray-Coquard, I | 1 |
| Cassier, P | 1 |
| Blay, JY | 1 |
| Barr, P | 1 |
| Fu, P | 1 |
| Lazarus, H | 1 |
| Kane, D | 1 |
| Meyerson, H | 1 |
| Hartman, P | 1 |
| Reyes, R | 1 |
| Creger, R | 1 |
| Stear, K | 1 |
| Laughlin, M | 1 |
| Tse, W | 1 |
| Cooper, B | 1 |
| Lima, CB | 1 |
| Iglesias, KB | 1 |
| Andrade, ZA | 1 |
| Reddy, N | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Deeb, G | 1 |
| Roth, M | 1 |
| Vaughn, M | 1 |
| Knight, J | 1 |
| Wallace, P | 1 |
| Czuczman, MS | 1 |
| Caragacianu, D | 1 |
| Alexander, HR | 1 |
| Tangrea, MA | 1 |
| Morita, SY | 1 |
| Schafer, P | 1 |
| Muller, G | 2 |
| Stirling, D | 1 |
| Royal, RE | 1 |
| Cibeira, MT | 1 |
| Rozman, M | 1 |
| Segarra, M | 1 |
| Lozano, E | 1 |
| Rosiñol, L | 1 |
| Cid, MC | 1 |
| Filella, X | 1 |
| Bladé, J | 1 |
| Kale, R | 1 |
| Tayade, P | 1 |
| Saraf, M | 1 |
| Juvekar, A | 1 |
| Sanborn, SL | 1 |
| Cooney, MM | 1 |
| Dowlati, A | 1 |
| Brell, JM | 1 |
| Krishnamurthi, S | 1 |
| Gibbons, J | 1 |
| Bokar, JA | 1 |
| Nock, C | 1 |
| Ness, A | 1 |
| Remick, SC | 1 |
| D'Amato, RJ | 2 |
| Loughnan, MS | 1 |
| Flynn, E | 1 |
| Ziegler, J | 1 |
| Minchinton, AI | 1 |
| Fryer, KH | 1 |
| Wendt, KR | 1 |
| Clow, KA | 1 |
| Hayes, MM | 1 |
| Ip, M | 1 |
| Gorin, MB | 1 |
| Ono, M | 2 |
| Kuwano, M | 2 |
| McCarty, MF | 1 |
| Or, R | 1 |
| Feferman, R | 1 |
| Shoshan, S | 1 |
| Wells, WA | 1 |
| Bauer, KS | 1 |
| Dixon, SC | 1 |
| Joseph, IB | 1 |
| Isaacs, JT | 1 |
| Shimazawa, R | 1 |
| Miyachi, H | 1 |
| Takayama, H | 1 |
| Kuroda, K | 1 |
| Kato, F | 1 |
| Kato, M | 1 |
| Hashimoto, Y | 1 |
| Burton, E | 1 |
| Prados, M | 1 |
| Kotoh, T | 1 |
| Dhar, DK | 1 |
| Masunaga, R | 1 |
| Tabara, H | 1 |
| Tachibana, M | 1 |
| Kubota, H | 1 |
| Kohno, H | 1 |
| Nagasue, N | 1 |
| Verheul, HM | 1 |
| Yuan, J | 1 |
| Konno, H | 1 |
| Tanaka, T | 1 |
| Baba, M | 1 |
| Kanai, T | 1 |
| Miller, MT | 1 |
| Strömland, K | 1 |
| Moreira, AL | 1 |
| Friedlander, DR | 1 |
| Shif, B | 1 |
| Kaplan, G | 1 |
| Zagzag, D | 1 |
| Verougstraete, C | 1 |
| Marriott, JB | 1 |
| Dalgleish, AG | 1 |
| Sauer, H | 1 |
| Günther, J | 1 |
| Hescheler, J | 1 |
| Wartenberg, M | 1 |
| Bay, JO | 1 |
| Tournilhac, O | 1 |
| Kakimoto, T | 1 |
| Sjak-Shie, NN | 1 |
| Vescio, RA | 1 |
| Schreiber, S | 1 |
| Ackermann, J | 1 |
| Obermair, A | 1 |
| Kaufmann, H | 1 |
| Urbauer, E | 1 |
| Aletaha, K | 1 |
| Gisslinger, H | 1 |
| Chott, A | 1 |
| Huber, H | 1 |
| Drach, J | 1 |
| Hussein, MA | 2 |
| Adlard, JW | 1 |
| Myoung, H | 1 |
| Hong, SD | 1 |
| Kim, YY | 1 |
| Hong, SP | 1 |
| Kim, MJ | 1 |
| Bosco, AA | 1 |
| Machado, RD | 1 |
| Li, C | 1 |
| Smith, D | 1 |
| Dahut, W | 1 |
| Duray, P | 1 |
| Hamilton, M | 1 |
| Tompkins, A | 1 |
| Steinberg, SM | 1 |
| Jones, E | 1 |
| Premkumar, A | 1 |
| Linehan, WM | 1 |
| Floeter, MK | 1 |
| Chen, CC | 1 |
| Dixon, S | 1 |
| Kohler, DR | 1 |
| Krüger, EA | 1 |
| Gubish, E | 1 |
| Pluda, JM | 1 |
| Zorat, F | 1 |
| Comar, C | 1 |
| Kikic, F | 1 |
| Festini, G | 1 |
| Mikala, G | 1 |
| Jákó, J | 1 |
| Vályi-Nagy, I | 1 |
| Steins, M | 1 |
| Retzlaff, S | 1 |
| Ginsburg, PM | 1 |
| Dassopoulos, T | 1 |
| Ehrenpreis, ED | 1 |
| Schlossman, RL | 1 |
| Ruiz, S | 1 |
| Kropff, M | 1 |
| Buechner, T | 1 |
| Combe, B | 1 |
| Tosi, P | 1 |
| Lundberg, LG | 1 |
| Lerner, R | 1 |
| Palmblad, J | 1 |
| Brock, CS | 1 |
| Douglas, ML | 1 |
| Reid, JL | 1 |
| Hii, SI | 1 |
| Jonsson, JR | 1 |
| Nicol, DL | 1 |
| Das, U | 1 |
| List, AF | 1 |
| Scherer, A | 1 |
| Strupp, C | 1 |
| Wittsack, HJ | 1 |
| Engelbrecht, V | 1 |
| Willers, R | 1 |
| Germing, U | 1 |
| Gattermann, N | 1 |
| Haas, R | 1 |
| Mödder, U | 1 |
| Domański, D | 1 |
| Hus, M | 1 |
| Soroka-Wojtaszko, M | 1 |
| Arrieta, O | 1 |
| Guevara, P | 1 |
| Tamariz, J | 1 |
| Rembao, D | 1 |
| Rivera, E | 1 |
| Sotelo, J | 1 |
| Kaushal, V | 1 |
| Kohli, M | 1 |
| Fink, L | 1 |
| Mehta, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer[NCT00357500] | Phase 2 | 101 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| "Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study"[NCT00744536] | Phase 2 | 20 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| A Prospective Single-center Study on the Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS[NCT06004765] | Phase 4 | 138 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma[NCT00151281] | Phase 2 | 25 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Randomized Study Comparing Carboplatin and Thalidomide With Carboplatin Alone in Patients With Stage Ic - IV Ovarian Cancer[NCT00004876] | Phase 2 | 30 participants (Anticipated) | Interventional | 1999-08-31 | Completed | ||
| Salvage Treatment With Lenalidomide and Dexamethaosne(LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)[NCT00786851] | Phase 2 | 33 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704] | Phase 1 | 29 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| Thalidomide for the Treatment of Cytopenias of Patients With Low Risk Myelodysplastic Syndromes[NCT00455910] | Phase 2 | 112 participants | Interventional | 2003-01-31 | Completed | ||
| A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallop[NCT02584478] | Phase 3 | 294 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| [NCT02748772] | Phase 3 | 148 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab[NCT00783367] | Phase 2 | 50 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles[NCT00049296] | Phase 1 | 26 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation[NCT00004635] | Phase 3 | 159 participants (Actual) | Interventional | 2000-03-01 | Completed | ||
| Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.[NCT01243476] | Phase 3 | 61 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.61 |
27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.31 |
Proportion of patients alive at 27 weeks without progressive disease (PD) and having tolerated therapy. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: 27 weeks
| Intervention | proportion of patients (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | .25 |
As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Best response was regarded as best response at any single assessment. Response was defined as follows: complete resolution of all demonstrable tumor, complete response (CR); >/=50% decrease in the product of the 2 maximum perpendicular diameters relative to the baseline evaluation, partial response (PR); <50% decrease and <25% increase in product of diameters, stable disease (SD); and >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease (PD). For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed at study entry, every 9 weeks on treatment and at treatment discontinuation, up to 27 weeks.
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable | |
| 5-drug Metronomic Antiangiogenic Regimen | 1 | 12 | 36 | 47 | 1 |
Stromal angiogenesis was assessed using blood vascular and perivascular markers, including VEGFR-1, VEGFR-2, CD34, and a-SMA, as well as lymphatic vascular markers ofVEGFR-3, podoplanin, and Lyve-1. (NCT00151281)
Timeframe: 38 months
| Intervention | pg/mL (Median) |
|---|---|
| RT-PEPC Drug Therapy | 109.5 |
measured by overall Response Rate (ORR), which includes Complete response and partial response. (NCT00151281)
Timeframe: 38 months
| Intervention | percentage of patients (Number) |
|---|---|
| Study Treatment Arm | 73 |
Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. (NCT00151281)
Timeframe: 38 months
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 or 4 neutropenia | Anemia | Thrombocytopenia | Fatigue | Constipation | Cough | Nausea | Neuropathy | Dyspnea | Rash | |
| RT-PEPC Drug Therapy | 14 | 1 | 4 | 22 | 14 | 14 | 13 | 13 | 11 | 10 |
"QoL assessments were obtained with version 3 of the Functional Assessment of Cancer Therapy-General (FACT-G) instrument. The FACT-G is comprised of four subscales: physical well-being (7-items, score range 0-28), social/family well-being (7-items, score range 0-28), emotional well-being (6-items, score range 0-24), and functional well-being (7-items, score range 0-28). Users of the FACT-G are able to generate an overall score and four subscale scores with ranges and distributions that are sample-specific. All questions in the FACT-G use a 5-point rating scale (0 = Not at all to 4 = Very much) A higher number indicates a better Quality of Life, and has a possible range of 0-108 points.~ANOVA was used to compare the difference in the means of total score among the different time points (baseline, every 2M until 6M, and every 6M until PD). The mean of the total FACT-G scores at baseline and mean of total score at all timepoints (using ANOVA) are reported below." (NCT00151281)
Timeframe: baseline, every 2 months until Month 6, and every 6 months until disease progression
| Intervention | FACT-G score (Mean) | |
|---|---|---|
| Mean FACT-G Score at baseline | Mean Total FACT-G Score between all time points | |
| RT-PEPC Drug Therapy | 83.3 | 89.4 |
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
Response rate is defined as a complete response or partial response using anatomic criteria of the International Workshop Response Critieria (Cheson, 1999). (NCT00783367)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 | 14 |
| Cohort 2 | 13 |
Progression free survival time in months (NCT00783367)
Timeframe: 9 years from enrollment of first subject
| Intervention | months (Median) |
|---|---|
| Cohort 1 | 22.2 |
| Cohort 2 | 22.4 |
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00004635)
Timeframe: Date treatment consent signed to date off study, approximately 60 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Thalidomide | 117 |
| Placebo | 98 |
Time to progression is defined as follows: if the PSA returns to baseline (defined as the PSA value prior to starting leuprolide or goserelin) or increases to the absolute value of 5 ng/ml. (NCT00004635)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Thalidomide | 15 |
| Placebo | 9.6 |
77 reviews available for thalidomide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Studying molecular signaling in major angiogenic diseases.
Topics: Angiogenesis Inhibitors; Bevacizumab; Cetuximab; Everolimus; Humans; Imatinib Mesylate; Neoplasms; N | 2022 |
The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine.
Topics: Abnormalities, Drug-Induced; Animals; Biomarkers; Female; Gene Expression Regulation; Humans; Limb D | 2017 |
A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Humans; Multiple Myeloma; Neovascularization, Pathologic; Thalidomide; Tumo | 2017 |
Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Diabetic Retinopathy; Humans; Neovascularizat | 2017 |
Adhesion molecules and the extracellular matrix as drug targets for glioma.
Topics: Angiogenesis Inhibitors; Antibodies; Brain Neoplasms; Cell Adhesion Molecules; Disease Progression; | 2016 |
Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review).
Topics: Animals; Cell Communication; Humans; Immunomodulation; Lymphocytes; Neoplasms; Neovascularization, P | 2016 |
Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Mice; Mice, SC | 2017 |
[Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dia | 2008 |
Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis?
Topics: Abnormalities, Drug-Induced; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Blood | 2008 |
Judah Folkman's contribution to the inhibition of angiogenesis.
Topics: Allergy and Immunology; Angiogenesis Inhibitors; Animals; Cyclohexanes; History, 20th Century; Histo | 2008 |
Mechanism of action of lenalidomide in hematological malignancies.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pa | 2009 |
Thrombotic events in patients with cancer receiving antiangiogenesis agents.
Topics: Angiogenesis Inhibitors; Anticoagulants; Female; Follow-Up Studies; Humans; Immunologic Factors; Inc | 2009 |
Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
Topics: Cytokines; Humans; Immunologic Factors; Multiple Myeloma; Neovascularization, Pathologic; Primary My | 2010 |
Angiogenesis and invasion in glioma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevaciz | 2011 |
Hemangiomas - current therapeutic strategies.
Topics: Angiogenesis Inhibitors; Bleomycin; Child; Cyclophosphamide; Hemangioma; Humans; Interferons; Neovas | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; I | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical | 2011 |
Antiangiogenesis in myelodysplastic syndrome.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizuma | 2011 |
Deciphering the mystery of thalidomide teratogenicity.
Topics: Adaptor Proteins, Signal Transducing; Animals; Chick Embryo; Female; Fibroblast Growth Factor 8; Hum | 2012 |
Thalidomide, an antiangiogenic agent with clinical activity in cancer.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, P | 2002 |
Thalidomide for the treatment of relapsed and refractory multiple myeloma.
Topics: Cell Division; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Multiple | 2002 |
Clinical translation of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Cell Movement; Clinical Trials as Topic; Drug Resistance, Neoplasm; Genes, | 2002 |
[Multiple myeloma and neovascularization].
Topics: Animals; Humans; Multiple Myeloma; Neovascularization, Pathologic; Thalidomide | 2002 |
[Angiogenesis research--quo vadis?].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2003 |
New insights into the pharmacological and toxicological effects of thalidomide.
Topics: Animals; Cell Adhesion Molecules; Cytokines; Gene Expression Regulation; Humans; Interleukins; Neova | 2003 |
[Using thalidomide against pathological neovascularization].
Topics: Angiogenesis Inhibitors; Corneal Neovascularization; Humans; Neovascularization, Pathologic; Thalido | 2003 |
Molecular targets in the inhibition of angiogenesis.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Angiopoietins; Animals; Cell Division; Clinical Trials | 2003 |
Thalidomide for the treatment of acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Marrow; | 2003 |
Antiangiogenic therapy in hematologic malignancies.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple | 2004 |
The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Thalidom | 2004 |
[Thalidomide: (re)discovery of a not very dear old molecule].
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Male; Multiple Myeloma; Myelodysplastic Syndromes; Ne | 2003 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxyg | 2004 |
New drugs for treatment of multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Ars | 2004 |
Thalidomide and analogues: current proposed mechanisms and therapeutic usage.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Administration Schedule; Humans; Male; Neova | 2004 |
Hematopoietic cancer and angiogenesis.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Disease Progression; Endothelium, Vascular; Hematologic | 2004 |
Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
Topics: Angiogenesis Inhibitors; Animals; Cytokines; Humans; Neovascularization, Pathologic; Primary Myelofi | 2004 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; C | 2004 |
Antiangiogenic strategies in neuroblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cyclohexanes; Disea | 2005 |
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cel | 2005 |
Translational research in myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Apoptosis; Azacitidine; Bone Marrow; Cell Death; Enzyme Inhibitors; Humans; | 2004 |
[Anti-angiogenesis treatment for brain tumors--present and future].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Tr | 2005 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mul | 2005 |
Targeting angiogenesis for the treatment of sarcoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Neovascularizatio | 2006 |
The use of thalidomide in myeloma therapy as an effective anticancer drug.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Remodeling; Cell Proliferation; Humans; Killer | 2006 |
Targeted therapies in gynecologic cancers.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2006 |
[Angiogenesis and endothelial cells in blood neoplasms].
Topics: Angiogenesis Inhibitors; Bone Marrow; Endothelial Cells; Endothelium, Vascular; Growth Substances; H | 2006 |
Thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunolog | 2006 |
The thalidomide saga.
Topics: Antineoplastic Agents; Cytokines; Fibroblast Growth Factor 2; Humans; Immunosuppressive Agents; Lymp | 2007 |
Strategies for suppressing angiogenesis in gynecological cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dru | 2007 |
[Angiogenesis and lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bio | 2007 |
[Angiogenesis and breast cancer].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2007 |
[Development of anti tumor agents targeting angiogenesis].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enz | 1997 |
[Neovascularization and tumor development].
Topics: Angiostatins; Antibiotics, Antineoplastic; Antineoplastic Agents; Collagen; Cyclohexanes; Endostatin | 1998 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Endothelial Growth Factors; Female; Gas | 1999 |
Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses.
Topics: Eye Abnormalities; Female; History, 20th Century; HIV Infections; Humans; Infant, Newborn; Leprosy; | 1999 |
[Present and future treatment of age-related macular degeneration].
Topics: Animals; Clinical Trials as Topic; Diet Therapy; Forecasting; Humans; Interferon alpha-2; Interferon | 1999 |
Thalidomide as an emerging immunotherapeutic agent.
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Anti-Inflam | 1999 |
[Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
Topics: Angiogenesis Inhibitors; Bone Marrow; Clinical Trials as Topic; Humans; Multiple Myeloma; Neovascula | 2000 |
Recent advances in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Chromosome | 2000 |
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Bone Marrow; Cytokines; Humans; Multiple Myeloma; Neovascularization, Patho | 2000 |
Research on thalidomide in solid tumors, hematologic malignancies, and supportive care.
Topics: Antioxidants; DNA Damage; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Neoplasms; Neovascul | 2000 |
Thalidomide in the treatment of cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms | 2000 |
Current status of thalidomide in the treatment of cancer.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple Myeloma; | 2001 |
[Role of thalidomide in the treatment of multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neovascular | 2001 |
[Angiogenesis in patients with hematologic malignancies].
Topics: Aged; Aged, 80 and over; Bone Marrow; Clinical Trials as Topic; Female; Hematologic Neoplasms; Human | 2001 |
Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.
Topics: Anti-Inflammatory Agents; Clinical Trials as Topic; Crohn Disease; Humans; Immunosuppressive Agents; | 2001 |
Angiogenesis-dependent diseases.
Topics: Angiogenesis Inhibitors; Animals; Humans; Leukemia; Multiple Myeloma; Neovascularization, Pathologic | 2001 |
Angiogenesis in multiple myeloma.
Topics: Angiogenesis Inhibitors; Bone Marrow; Humans; Multiple Myeloma; Neovascularization, Pathologic; Prog | 2001 |
Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic | 2001 |
Thalidomide: new indications?
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Humans; Multiple Myeloma; Neoplasm Metastasis; Neov | 2001 |
Antiangiogenic therapy in multiple myeloma.
Topics: Angiogenesis Inhibitors; Drug Therapy, Combination; Endothelial Growth Factors; Humans; Lymphokines; | 2001 |
[New observations support the significance of angiogenesis in myeloma].
Topics: Angiogenesis Inhibitors; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Thalid | 2001 |
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Smal | 2002 |
A radical approach to cancer.
Topics: 2-Methoxyestradiol; Anaerobiosis; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxida | 2002 |
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezo | 2002 |
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptos | 2002 |
23 trials available for thalidomide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxi | 2014 |
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.
Topics: Aged; Aged, 80 and over; Biomarkers; Endothelial Cells; Humans; Lenalidomide; Leukemia, Myelomonocyt | 2014 |
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2011 |
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; | 2012 |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combin | 2012 |
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorub | 2003 |
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Bone Marrow; Disease-Free Survival; Female; | 2003 |
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitor | 2004 |
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Humans; Microcirculation | 2004 |
Phase II study of thalidomide in patients with metastatic malignant melanoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Fi | 2004 |
The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
Topics: Administration, Oral; CD8-Positive T-Lymphocytes; Cytokines; Enzyme-Linked Immunosorbent Assay; Flow | 2005 |
The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytokines; Dexamethasone; Female; | 2004 |
A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
Topics: Aged; Angiogenesis Inhibitors; Apoptosis; Biomarkers; Bone Marrow Cells; Cytokines; Dose-Response Re | 2005 |
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Male; Middle Aged; Neovascu | 2006 |
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Topics: Administration, Oral; Adult; Aged; Anemia; Anemia, Myelophthisic; Female; Hemoglobins; Humans; Janus | 2006 |
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, CD; Biomarkers, Tumor; Disease-Free Surv | 2007 |
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2007 |
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, CD; Biomarkers, Tumor; Dose-Response Relationship, D | 2007 |
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; F | 2007 |
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progre | 2008 |
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Endot | 2001 |
Efficacy and safety of thalidomide in patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Dose-Response Relation | 2002 |
135 other studies available for thalidomide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Cell Proliferation; Chemistry, Pharmaceutical; Drug Des | 2009 |
Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
Topics: Angiogenesis Inhibitors; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Guanine Nucleotide Exchange | 2021 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
The effect of dual-frequency sonication in the presence of thalidomide angiogenesis inhibitor and nanomicelles containing doxorubicin on inhibiting the growth and angiogenesis of breast adenocarcinoma in vivo.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Doxorubicin; Female; Mice; Mice, Inbred BALB C; Ne | 2022 |
Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Delivery Syste | 2019 |
Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation.
Topics: Angiogenesis Inhibitors; Animals; Calcium-Binding Proteins; Cell Adhesion Molecules; Cycloheximide; | 2020 |
Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Macrophages; Mice; Mice, Inbred BALB C; | 2020 |
Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2 in Crohn's Disease.
Topics: Adolescent; Angiogenesis Inhibitors; Angiopoietin-2; Biomarkers; Blotting, Western; Case-Control Stu | 2021 |
Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endothelial Cells; Fl | 2021 |
TNF-α-induced LRG1 promotes angiogenesis and mesenchymal stem cell migration in the subchondral bone during osteoarthritis.
Topics: Animals; Cell Movement; Gene Expression Regulation; Glycoproteins; Human Umbilical Vein Endothelial | 2017 |
Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response | 2017 |
Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; | 2017 |
Transcriptomic Analysis of Thalidomide Challenged Chick Embryo Suggests Possible Link between Impaired Vasculogenesis and Defective Organogenesis.
Topics: Animals; Chick Embryo; Gene Expression Profiling; Neovascularization, Pathologic; Organogenesis; Tha | 2017 |
Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
Topics: Acitretin; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationship, Dru | 2018 |
Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Topics: Bortezomib; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Coculture Techniques; Down | 2018 |
Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation | 2018 |
Recent studies on the thalidomide and its derivatives.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Humans; Multiple Myeloma; Neoplasms; Neovascular | 2018 |
Cetirizine and thalidomide synergistically inhibit mammary tumorigenesis and angiogenesis in 7,12-dimethylbenz(a)anthracene-treated rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Ce | 2018 |
The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Dendritic Cells; Female; Forkhead Transcription Factors; Humans; Imm | 2013 |
Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide.
Topics: Angiogenesis Inhibitors; Arteriovenous Fistula; Humans; Models, Biological; Neovascularization, Path | 2013 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug R | 2014 |
Standardization of a method to study angiogenesis in a mouse model.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Hemoglobins; | 2013 |
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Mode | 2014 |
Thalidomide influences atherogenesis in aortas of ApoE(-/-)/LDLR (-/-) double knockout mice: a nano-CT study.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Aortic Diseases; Aortography; Apolipoproteins E; Atheroscle | 2014 |
In vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Female; | 2014 |
Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Boron Compounds; Boron Neutron C | 2015 |
The preclinical activity of lenalidomide in indolent urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cerebrosides; Drug Screening Assays, | 2014 |
Investigating the role of angiogenesis in systemic lupus erythematosus.
Topics: Adult; Angiogenesis Inhibitors; Autoantibodies; Biomarkers; Endostatins; Female; Fibroblast Growth F | 2015 |
[Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Benzamides; Humans; Imatinib Mesylate; Indoles; Ne | 2015 |
Development of thalidomide-loaded biodegradable devices and evaluation of the effect on inhibition of inflammation and angiogenesis after subcutaneous application.
Topics: Acetylglucosaminidase; Animals; Biocompatible Materials; Calorimetry, Differential Scanning; Disease | 2015 |
Improvement of in vivo anticancer and antiangiogenic potential of thalidomide derivatives.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proli | 2015 |
Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Human Umbilica | 2015 |
Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer.
Topics: Animals; Apoptosis; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Gene Expressi | 2015 |
Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats.
Topics: Cells, Cultured; Down-Regulation; Drug Evaluation, Preclinical; Human Umbilical Vein Endothelial Cel | 2016 |
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2016 |
Lenalidomide induces apoptosis and inhibits angiogenesis via caspase‑3 and VEGF in hepatocellular carcinoma cells.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Pro | 2016 |
Thalidomide and thalidomide transformed by pH-dependent hydrolysis or by liver enzyme treatment does Not impede the proliferation of endothelial cells.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Cells, Cultured; Endothelial Cells; Humans; Hydrogen-Io | 2008 |
Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Ce | 2008 |
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Hel | 2009 |
Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy.
Topics: Aged; Humans; Male; Neovascularization, Pathologic; Primary Myelofibrosis; Stevens-Johnson Syndrome; | 2009 |
Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Carcino | 2009 |
The antiangiogenic effect of thalidomide on occult liver metastases: an in vivo study in mice.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Colonic Neoplasms; Female; Image Processing, Compu | 2009 |
Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia.
Topics: Actins; Angiogenesis Inhibitors; Animals; Blotting, Western; Chemokine CXCL1; Coronary Vessels; Dise | 2009 |
Thalidomide inhibition of vascular remodeling and inflammatory reactivity in the quinolinic acid-injected rat striatum.
Topics: Angiogenesis Inhibitors; Animals; Astrocytes; Blood Vessels; Cell Survival; Corpus Striatum; Gliosis | 2009 |
Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).
Topics: Angiogenesis Inhibitors; Cell Adhesion; Cell Division; Cell Movement; Cells, Cultured; Crohn Disease | 2010 |
Targeted therapies: Thalidomide in lung cancer therapy-what have we learned?
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Lung Neoplasms; Neovascularization, Patho | 2010 |
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic | 2008 |
Antitumor and antiangiogenic effects of GA-13315, a gibberellin derivative.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, | 2012 |
Treatment considerations for primary myelofibrosis.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Chr | 2010 |
Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; | 2011 |
Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Carboxymethylcellulose Sodium; Carcinoma, He | 2011 |
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Apoptosis Regulatory Proteins; Bone Marrow Cells; Cel | 2011 |
Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos.
Topics: Angiogenesis Inhibitors; Animals; Blastoderm; Blood Vessels; Cell Line, Tumor; Embryo, Nonmammalian; | 2011 |
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carbopla | 2012 |
Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapy.
Topics: Angiogenesis Inhibitors; Animals; Contrast Media; Disease Models, Animal; Immunohistochemistry; Iohe | 2012 |
Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Female; Fibroblast Growth Factor 1; Gene Exp | 2012 |
Blood vessel normalization in the hamster oral cancer model for experimental cancer therapy studies.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Capillary Permeability; Case-Control Studies; Cheek | 2012 |
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic A | 2012 |
Adipose tissue mass can be regulated through the vasculature.
Topics: Adipose Tissue; Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Biphenyl Comp | 2002 |
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Endothelial Growth Factors; Female; Fibroblast Gr | 2002 |
Despite checkered past, thalidomide and its analogues show potential.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunosuppressive A | 2002 |
Antimyeloma efficacy of thalidomide in the SCID-hu model.
Topics: Angiogenesis Inhibitors; Animals; Biotransformation; Bone Transplantation; Cell Division; Endothelia | 2002 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Drug Administration Schedule | 2003 |
[The thalidomide story: a new chapter].
Topics: Humans; Neovascularization, Pathologic; Teratogens; Thalidomide | 2003 |
Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Base Sequence; Cell Line, Tumor; DNA, Complementary; Down-R | 2003 |
Endothelial cells in the bone marrow of patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Marrow; Capillaries; Case-Control Studies; Cell Separation | 2003 |
Effects of thalidomide on parameters involved in angiogenesis: an in vitro study.
Topics: Angiogenesis Inhibitors; Cell Division; Cells, Cultured; Endothelial Growth Factors; Endothelium, Va | 2003 |
Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Endothelium, Vascular; Humans; Immunohistochemis | 2003 |
Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition.
Topics: Angiogenesis Inhibitors; Animals; Cell Division; Cell Hypoxia; Cytokines; Endothelium, Vascular; Mic | 2003 |
[Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
Topics: Angiogenesis Inhibitors; Animals; Body Weight; Carcinoma, Hepatocellular; Disease Models, Animal; Fl | 2003 |
Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Biochemistry; Cell Division; Drug Screeni | 2004 |
Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; Co | 2004 |
Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Topics: Adult; Aged; Angiogenesis Inhibitors; Blood Proteins; Bone Marrow; Female; Fibroblast Growth Factor | 2004 |
s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line.
Topics: Angiogenesis Inhibitors; Apoptosis; Cell Line, Tumor; Cell Survival; DNA, Neoplasm; Gene Expression | 2004 |
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Humans; Immunoh | 2004 |
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; D | 2004 |
Differential effects of antiangiogenic compounds in neovascularization, leukocyte recruitment, VEGF production, and tumor growth in mice.
Topics: Acetylglucosaminidase; Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Carcinoma, Ehrlic | 2004 |
The new cancer blockers.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2004 |
Circulating endothelial progenitor cells in multiple myeloma: implications and significance.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Cells, Cultured; Endothelium, Vascular; Fem | 2005 |
Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Division; DNA Prime | 2005 |
Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin?
Topics: Angiogenesis Inhibitors; Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Male; Neovasculariza | 2005 |
[Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice].
Topics: Animals; Cell Proliferation; Cyclophosphamide; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude | 2005 |
Antiangiogenic activity of beta-eudesmol in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Astrocytes; Cell Adhesion; Cell Movement; Cell Proliferation; Cell | 2005 |
Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Angiogenesis Inducing Agents; Angiogenesis Inhib | 2005 |
Thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apop | 2005 |
Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell P | 2005 |
Effect of thalidomide on colorectal cancer liver metastases in CBA mice.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Fibroblast Growth Fact | 2005 |
[Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice].
Topics: Animals; Antigens, CD34; Cell Line, Tumor; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Ma | 2005 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Image Proc | 2006 |
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Doc | 2006 |
Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Chromatography, High Pressure L | 2006 |
Synthesis and evaluation of 4-[(18)F]fluorothalidomide for the in vivo studies of angiogenesis.
Topics: Animals; Carcinoma, Lewis Lung; Endothelial Cells; Humans; Isotope Labeling; Metabolic Clearance Rat | 2006 |
Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Nucleus; Cell Proliferation; Diethylstilbestrol; E | 2006 |
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Female; Fibroblast | 2006 |
The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
Topics: Animals; Apoptosis; Blood Vessels; Caspase 3; Cell Proliferation; Child, Preschool; Female; Humans; | 2006 |
Differential angiogenic regulation of experimental colitis.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; CD4-Positive T-Lymphocytes; Colitis; Colon; Disease | 2006 |
Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.
Topics: Animals; Apoptosis; Cells, Cultured; Drug Therapy, Combination; Electrophysiology; Endothelial Cells | 2007 |
Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice.
Topics: Animals; Bleomycin; Cell Differentiation; Cell Line; Cell Line, Transformed; Collagen Type I; Collag | 2007 |
Role of renal cortical neovascularization in experimental hypercholesterolemia.
Topics: Angiogenesis Inhibitors; Animals; Atherosclerosis; Blood Pressure; Cell Proliferation; Disease Model | 2007 |
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Prol | 2007 |
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; CD57 An | 2007 |
Thalidomide failed to inhibit angiogenesis and fibrosis in hepatic schistosomiasis of the mouse.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Female; Liver; Liver Cirrhosis; Male; Mice | 2007 |
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; An | 2008 |
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; An | 2008 |
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; An | 2008 |
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; An | 2008 |
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclo | 2008 |
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Topics: Aged; Angiogenic Proteins; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Capillarie | 2008 |
Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice.
Topics: Angiogenesis Inhibitors; Animals; beta-Cyclodextrins; Biological Availability; Calorimetry, Differen | 2008 |
Thalidomide is an inhibitor of angiogenesis.
Topics: Animals; Chick Embryo; Cornea; Fibroblast Growth Factor 2; In Vitro Techniques; Neovascularization, | 1994 |
Rethinking thalidomide.
Topics: Animals; Diabetic Retinopathy; Eye; Humans; Macular Degeneration; Neovascularization, Pathologic; Ra | 1995 |
Angiogenesis research enjoys growth spurt in the 1990s.
Topics: Antineoplastic Agents; Cyclohexanes; Drugs, Investigational; Endothelial Growth Factors; Humans; Int | 1996 |
The effect of thalidomide on experimental tumors and metastases.
Topics: Animals; Combined Modality Therapy; Female; Mice; Neoplasm Metastasis; Neoplasms, Experimental; Neov | 1996 |
Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide.
Topics: Adult; Choroid; Choroid Diseases; Female; Fluorescein Angiography; Fundus Oculi; Humans; Immunosuppr | 1996 |
Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis.
Topics: Animals; Antineoplastic Agents; Callithrix; Fish Oils; Gene Expression; Humans; Hyperplasia; Inflamm | 1997 |
Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs.
Topics: Animals; Cricetinae; DNA; Foreign-Body Reaction; Granuloma; Hydroxyproline; Male; Neovascularization | 1998 |
A cautious comeback for thalidomide.
Topics: Abnormalities, Drug-Induced; Antineoplastic Agents; Graft vs Host Disease; HIV Wasting Syndrome; Hum | 1998 |
Starving cancer into submission. EntreMed, Inc.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Humans; Mice; Neoplasms; Neov | 1998 |
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.
Topics: Animals; Antineoplastic Agents; Aorta, Thoracic; Cell Division; Cells, Cultured; Coculture Technique | 1998 |
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.
Topics: Animals; Antineoplastic Agents; Enzyme-Linked Immunosorbent Assay; Genistein; Granulocyte-Macrophage | 1998 |
Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide.
Topics: Animals; Fibroblast Growth Factor 2; Humans; Mice; Mice, Inbred BALB C; Neovascularization, Patholog | 1999 |
Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.
Topics: Animals; Endothelial Growth Factors; Esophageal Neoplasms; Female; Fibroblast Growth Factor 2; Human | 1999 |
Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits.
Topics: Administration, Oral; Animals; Cornea; Female; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experiment | 1999 |
Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro.
Topics: Animals; Cell Division; Cornea; Endothelium, Vascular; Fibroblast Growth Factor 2; Glioma; Humans; N | 1999 |
Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals.
Topics: Angiogenesis Inhibitors; Animals; Capillaries; Cell Differentiation; Cell Line; Drug Combinations; E | 2000 |
[Importance of thalidomide in the treatment of cancer].
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Neoplasms; Neovas | 2000 |
Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Chromosome Deletion; Chromosom | 2000 |
Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug | 2001 |
Differential effects of thalidomide on angiogenesis and tumor growth in mice.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Ehrlich Tumor; Granuloma, Foreign-Body; Male; Mice; Neo | 2001 |
Targeting of vasculature in cancer and other angiogenic diseases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antigens, CD; Arthritis, Rheumatoid; Diabetic Retin | 2001 |
Thalidomide and HIV: several possible uses.
Topics: AIDS-Related Opportunistic Infections; Cachexia; Clinical Trials as Topic; HIV Infections; Humans; N | 1995 |
Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.
Topics: Angiogenesis Inhibitors; Bone Marrow; Drug Evaluation; Humans; Neovascularization, Pathologic; Prima | 2001 |
Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Division; Drug Resistance, Neoplasm; H | 2002 |
[Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy].
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Contrast Media; Female; Gadolinium DTPA; Humans; | 2002 |
Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers; Drug Evaluation; Endothelial Growth Factors; Femal | 2002 |
Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell D | 2002 |
Endothelial dysfunction in antiangiogenesis-associated thrombosis.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Neovascularization, Pathologic; Thalidomide; | 2002 |